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TITLE OF THE ABSTRACT: Assessment of treatment failure with Artemisinin combination therapy in 
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WORD COUNT: 471 words 
OBJECTIVES: 
The study was done to assess the incidence of treatment failure to Artemisinin combination therapy 
(ACT) by studying the clinical response and the parasitological clearance in patients with falciparum 
malaria. The drug levels were assessed and the basic drug pharmacokinetic variables were correlated 
with treatment response. 
METHODS: 
In a prospective cohort study from October 2012 to June 2014, fifty four slide confirmed cases of 
falciparum malaria on ACT were enrolled. Clinical response was characterised by fever clearance time 
(FCT), assessed by measurement of body temperature till defervescence. Parasitological response was 
measured by parasite clearance time (PCT), which is the time to the first negative peripheral smear, with 
undetectable asexual forms. Seventeen patients with severe malaria requiring parenteral therapy were 
treated with 2.4 mg/kg intravenous artesunate according to WHO guidelines 2010 for treatment of severe 
malaria. Venous blood samples were obtained on day 3 of ACT at multiple time points (0 - 240 minutes) 
after artesunate dose and the plasma concentrations of artesunate and dihydroartemisinin were 
measured using liquid chromatography-tandem mass spectrometry. The observed maximum plasma 
concentrations, four hour exposure and time to maximum concentrations were reported. The host factors, 
severity of infection, organ dysfunction and drug concentrations were correlated with treatment response. 
 Parasite clearance times and fever clearance times were assessed by means of survival analysis with use 
of the Kaplan Meier method, and data analysis was done by means of student’s t test, the chi – square test 
or Mann- Whitney U test, as appropriate. Boot strap analysis was done to correlate factors affecting 
treatment response in a larger population. 
RESULTS 
The proportion of patients with early treatment failure as defined by persistent parasitemia on day 3 of 
ACT was 25.5%. Recrudescence as defined by relapse of fever post treatment with ACT was 9.3%.The 
median parasite clearance time was estimated to be 36 hours (95%CI: 27.08 – 44.91). The median fever 
clearance time was estimated to be 24 hours (95% CI: 18.69 – 29.30). Among the patients with delayed 
parasite clearance, the mean clearance time was found to be 77.53 hours and in those with delayed fever 
defervescence, the mean fever clearance time was 84.6 hours. Higher age, acute kidney injury, acute 
hepatic injury, metabolic acidosis and hyperparasitemia were found to be risk factors in univariate 
analysis. Basic pharmacokinetic variables assessed were similar between responders and non responders. 
Multivariate logistic regression analysis showed higher age to be a risk factor. Boot strap analysis did not 
reveal any association between host factors or drug concentrations to the treatment response. 
CONCLUSIONS 
The susceptibility of Plasmodium falciparum to artemisinin combination therapy is declining in South 
India resulting in early treatment failure. The pharmacokinetics of artesunate and dihydroartemisinin 
was not different between the responders and non responders suggesting that a parasite factor is 
contributing to decreased susceptibility to ACT. Molecular studies are required to confirm resistance. 
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1. INTRODUCTION 
 
Anti malarial drug resistance is defined as persistence or recurrence of malarial parasites after 
appropriate drug treatment(1). Artemisinin based combination therapy (ACT) is the current 
recommended first line anti malarial therapy in management of severe malaria(2).The 
changes in  parasite susceptibility to ACT  detected by therapeutic efficacy studies is essential 
for tracking artemisinin resistance(3).Therapeutic efficacy studies aid in the identification of  
proportion of patients who are parasitemic on day 3,which is the most strong and reliable 
factor  to identify treatment failure(1,3). Rates of treatment failure exceeding 10% warrant a  
change in the antimalarial treatment policy in the region(4). 
Infection with Plasmodium falciparum species sensitive to ACT clear within two days of 
initiation of therapy as compared to resistant parasites where a delay in clearing of the 
parasites was observed .The decreasing response to artemisinin was first observed in 
Cambodia – Thailand border which has since become the epicentre of  emergence and spread 
of artemisinin resistance(5,6).  India shares a common border with Thailand and Bangladesh 
which have thick forests and landscape favouring vector transmission compounded with  poor 
accessibility to health care, which could potentiate entry of resistance from the Greater 
Mekong Region(7).Delayed susceptibility to artesunate and sulphadoxine based combination 
therapy has been recently reported in three eastern states of Arunachal Pradesh, Mizoram and 
Tripura(8).We have been observing a trend of delayed defervsecence of fever and persistence 
of parasites in our population. Hence, this study was designed to identify the incidence of 
treatment failure with Artemisinin combination therapy (ACT) among patients with 
falciparum malaria presenting to Christian Medical College, Vellore, a tertiary care centre in 
South India. 
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2. AIM 
 
To assess treatment failure with Artemisinin combination therapy (ACT) in management of 
Plasmodium falciparum malaria in patients presenting to Christian Medical College, a tertiary 
care hospital in South India. 
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3. OBJECTIVES 
 
1) To determine the incidence of treatment failure in falciparum malaria in patient treated with ACT. 
2) To assess the clinical response (CR) and parasitological clearance (PC) of Plasmodium falciparum 
in patients treated with Artemisinin combination therapy (ACT). 
3) To determine the serum concentrations of artesunate and dihydroartemisinin and correlate clinical 
response with the same. 
4) To study the variability in pharmacokinetic parameters of artesunate and dihydroartemisinin 
between patients who respond to therapy and in patients with early treatment failure. 
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4. REVIEW OF LITERATURE 
 
4.1 MALARIA - EPIDEMIOLOGY 
 
Malaria is a tropical disease which is caused by five species of genus Plasmodium causing 
human infection. The species are mainly Plasmodium falciparum, ovale, vivax, malariae and 
knowlesi.Infections caused by falciparum and vivax are of great public health concern in the 
tropical countries. Active transmission is documented in 104 countries and are presently 
endemic for malaria as of WHO global malaria report 2013(2).Africa contributes to 80% of 
the malarial deaths ,of which 77% are in the paediatric age group. Malaria is transmitted by 
female Anopheles mosquito. Of the 400 species identified, 30 are vectors of significance in 
transmission. Two of the widely used antimalarials are derived from plant sources – 
artemisinin derivative (Artemisia annua), Quinine (Cinchona) are currently in use in areas 
endemic for malaria transmission. 
4.1.1 TRENDS IN SOUTH EAST ASIA – SUMMARY OF WORLD MALARIA 
REPORT 2013  
 Diagnosed malarial infections, confirmed by light microscopy reported in the South east 
region, during the time span of the year 2000 - 2012 decreased from 2.9 to 2 million. 
96% of the reported cases of malaria in 2012 were contributed by the three countries: India 
(52%), Myanmar (24%) and Indonesia (22%).Considering the Indian scenario, the number of 
confirmed cases being reported  have declined from 2 million in the year  2000 to 1.1 million 
in the year 2011.The provided national statistics suggest that the country is enroute to 
achieving  a decrement in the incidence of malaria by 50% - 75% by 2015(2). The mortality 
due to malaria in the region has also decreased from 5500 to 1200 between the time span of 
12 years, from 2000 and 2012. India accounts to 42% of malarial deaths in the year 2012. 
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Figure 1 The country wise statistics of malaria [Adapted from WHO malaria report 2013] 
4.1.2 THE INDIAN SCENARIO 
 
95% population live in malaria endemic areas and 80% of malaria reported in the country is 
confined to areas which are hilly terrains, inaccessible to medical care(9). The number of 
cases has been on a decline from the year 2002(10).50 % of reported cases are caused by 
falciparum species and 50% by vivax species. North and north eastern India are endemic for 
falciparum infection. The common anopheles species found include An. fluviatilis, stephensi, 
dirus, minimus, annularis and culicifacies.Artesunate and sulphadoxine- pyrimethamine 
combination is currently recommended first line treatment. Combination therapy based on 
quinine is recommended for management of treatment failure. 
The case distribution and the surveillance measures are summarised in Figure 2. 
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Figure 2 Epidemiology and interventional strategies [adapted from WHO malaria report 2013] 
 
Public sector based interventions by the NMEP have contributed significantly to the decline 
in incidence of malaria cases. Presently malaria diagnostic tests as well as ACT has been 
administered free of cost in the public sector. Extensive preventive measures are in place 
which includes larval control as well as the larval control measures. 
The impact of these diagnostic and treatment interventions are summarised in figure 3. 
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Figure 3 Impact of interventions and surveillance[Adapted from nvbdcp.gov.in](9) 
The national epidemiological indicators also show a marked decline over the last 5 years. 
Annual Parasite Incidence (API) rate has decreased from 2.12/1000 in 2001 to 0.88/1000 in 
2012(10).Slide Falciparum rate has also reduced significantly. 
In the state of Tamilnadu, 74% are reported from Chennai the remaining 8.4% are from 
Vellore, Tuticorin, Erode, Dindigul, Tiruchengode, Salem, Tiruvallur and Tiruvottriyur(11). 
In contrary to the national and WHO data, which is reassuring ,a study published in The 
Lancet in 2010 by Dhingra et al(12) have showed that the malarial deaths are grossly 
underestimated and they had reported 1,20,000 deaths/year in India, as compared to national 
statistics which reported the number to be 1230 deaths. 
The mortality occurred in geographical areas which are highly endemic for falciparum 
infections. 
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4.2 THE PARASITE 
 
Transmission in humans occur by the bite of female Anopheles mosquito which harbours the 
Plasmodium sporozoites .The exoerythrocytic stage consists of the travel of the sporozoites to 
the invasion of hepatocytes. 
In the hepatocytes they multiply exceedingly creating tissue schizonts loaded with 
merozoites. P.falciparum schizonts rupture after a duration varying between 6 – 16 days 
releasing them into the blood stream.  
Erythrocytic cycle begins following the rupture of schizonts, where the released merozoites 
invade the red blood cells and undergo maturation through ring stages to mature trophozoites 
to form schizonts (the period of maturation differs between different species).The daughter 
merozoites continue infecting the available red blood cells, however few of them differentiate 
to sexual forms or gametocytes (male and female).The sexual forms help in continuation of 
transmission. 
The lifecycle of the parasite is summarised in Figure 4. 
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Figure 4: Lifecycle of Plasmodium falciparum [adapted from CDC] 
 
The genome of P.falciparum shows a marked genetic diversity between different geographic 
regions. Variation of the copy  number of genes in the genetic pool predisposes to 
development of antimalarial drug resistance(13). 
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4.2.1 PATHOPHYSIOLOGY 
 
Malaria is a disease which involves complex interaction between the host and the parasite, 
and the clinical presentation of the disease is sequelae of the host parasite interaction. The 
host parasite interaction and their physiology can be discussed under the following topics: 
4.2.1.1 Micro vascular sequestration: 
 
The parasitic forms in the erythrocytes cause formation of sticky knobs which are basically 
comprised of proteins induced by the parasite itself namely RESA,pfEMP1and 
pfEMP2.Human proteins like spectrin and actin also contribute to the same(14).Proteins 
interact with the host endothelial receptors such as CD36,chondroitin sulphate 
A(CSA),intercellular adhesion molecule-1 (ICAM-1),E-selectin, platelet endothelial cell 
adhesion molecule-1,vascular cell adhesion molecule-1 (VCAM-1),thrombomodulin (TM), 
(PECAM-1)and P-selectin(15).The end result of this interaction is intravascular 
sequestration, which is responsible for most of the manifestations of severe malaria including 
cerebral malaria as well as severe intravascular haemolysis. 
4.2.1.2 Parasite – Host interaction: 
 
The complex interaction of the malarial parasite with host immune system has not been 
identified. Available evidence suggests that the complex interaction up regulates the 
cytokines causing a cytokine storm mimicking a sepsis syndrome. 
4.2.1.3 Coagulation: 
 
Thrombocytopenia is the most common haematological abnormality in malaria. It occurs as a 
protective mechanism to compensate for intravascular sequestration of the parasitized red 
blood cells. Activation of tissue factor occurs during the course of infection , which causes 
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activation of the coagulation cascade, leading to a consumptive coagulopathy associated with 
elevated fibrin degradation products (d – dimer)(16).The platelets aggregate with red blood 
cells leading to thrombocytopenia and the degree of thrombocytopenia can provide the 
information as to the severity of the disease(16). 
4.3 THE ‘TISSUE FACTOR MODEL’ OF PATHOGENESIS 
 
Currently, the ‗Tissue factor Model‘ is the proposed model of pathogenesis to explain the 
haematological manifestations(17).It combined the previous two hypothetic models 
describing pathogenesis namely the ‗sequestration hypothesis‘, which makes the parasitized 
RBC the prime factor causing the disease manifestations, and the ‗cytokine hypothesis‘, 
which states that the inflammatory cascade triggered by the parasite causes the damage. 
According to the present tissue factor model, the parasitized red blood cells cause endothelial 
injury, which further leads to activation of tissue factor(17). This further activated the 
coagulation cascade and incites a state of systemic inflammatory response. The parasitized 
red blood cells form complex with platelets and the products of coagulation cascade and act 
as a ‗switch‘ to trigger further immune response, leading to endothelial injury. 
The capillary endothelium is affected in all the internal organs and depending on the severity 
of parasitemia is directly proportional to the severity of multi organ dysfunction. Cerebral 
malaria and black water fever are a few selected manifestations to prove this current 
hypothesis.  
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4.4 DIAGNOSIS OF MALARIA 
 
Parasite based diagnostic methods are the standard of care and reliable. Currently available 
methods include microscopy and rapid diagnostic tests. 
4.4.1 LIGHT MICROSCOPY: 
 
Microscopy helps in diagnosing the infection as well as to identify the species causing the 
infection. It also helps to quantify the severity of infection using the derived parameter, 
parasite index. Blood smears are used in diagnosis of malarial infection. The thick smear 
helps in diagnosis and the thin smears help in identification of the species. Ring-form 
trophozoites (rings) of Plasmodium falciparum are thin and delicate and measures up to a 
fifth of the diameter of the red blood cell. They contain chromatin dots, found on the 
periphery of the RBC (appliqué, accolé) (Figure 5a). Gametocytes of Plasmodium falciparum 
are sausage or crescent shaped, and measure about one and half times the diameter of an 
RBC. The macro gametocytes (female) are darker and stain deep blue when compared to the 
cytoplasm of the micro gametocytes (male) (Figure 5b). Chromatin is coarser and dark red 
with pigment in the macro gametocytes. The remnants of the RBC with parasites are called as 
Laveran's bib (Figure 5c). Schizonts are visualised in hyperparsitemic individuals (Figure 
5d). 
Parasite density is calculated by a standardised method by counting the number of parasitized 
erythrocytes per 200/500 white blood cells per field. 
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Figure 5 Microscopic appearance of stages of Falciparum 
[Adapted from CDC – Malaria gallery] 
 
4.4.2 RAPID DIAGNOSTIC KITS: 
 
The following antigens have been incorporated as a part of rapid diagnostic tests. Currently 
the antigens which are in use include: histidine rich protein(HRP2),plasmodium lactate 
dehydrogenase(Pldh) and aldolase  (18).These tests are of  use in resource limited  endemic  
5a 5b 
5c 5d 
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countries  like sub Saharan africa,where diagnosis by standard microscopy is time consuming 
with lack of expertise. 
4.3 MANAGEMENT OF MALARIA 
 
Principles of treatment include the use of combination therapy to prevent the parasite from 
acquiring resistance. This may occur following exposure to single pharmacological agent, 
and to retain the efficiency of the antimalarials.The mechanism of action of antimalarials are 
summarised in Figure 6. 
 
Figure 6 Mechanism of Antimalarials(19) 
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4.3.1 UNCOMPLICATED FALCIPARUM MALARIA: 
 
Uncomplicated malaria is defined as malarial infection with parasite index less than 5 percent 
with absent organ involvement and ability to take oral therapy. 
Treatment is guided based on the resistance patterns to chloroquine. 
4.3.1.1 In chloroquine sensitive areas: 
 
 This is mainly mid east, Central America, Haiti and Dominican Republic countries. 
Chloroquine is safely used as first line treatment. The dose is summarised as follows: 
600 mg oral base at diagnosis followed by 300 mg .The dose should be repeated at 6, 24 and 
48 hours. 
4.3.1.2 In chloroquine resistant areas: 
 
ACT are the recommended first line antimalarials for treatment of falciparum 
malaria(20).ACT are active against all developmental stages of the asexual forms of malaria 
which leads to rapid clearance time compared to other agents. ACTs have demonstrable 
activity against gametocytes; however it does not target mature forms. The following 
treatment regimens are recommended: 
4.3.1.2.1 Artemether + lumefantrine: 
It is given as combination tablets (1 tablet = 20 mg artemether and 120 mg lumefantrine). A 
total of 6 oral doses are recommended based on weight (25 - <35 kg: 3 tablets per dose, ≥35 
kg: 4 tablets per dose). The initial dose should be  followed by the second dose which is after 
8 hours followed by 1 dose twice daily for the following two days, for a duration of 3 days. 
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4.3.1.2.2 Artesunate + amodiaquine 
This is distributed as tablets containing 50 mg of artesunate and 153 mg base of amodiaquine. 
The recommended dose is 4 mg/kg of artesunate and 10 mg/kg of amodiaquine given once a 
day for three days. 
4.3.1.2.3 Artesunate + mefloquine 
This is given as separate tablets containing 50 mg of artesunate and 250 mg base of 
mefloquine, divided over 2 or 3 days to facilitate absorption. The recommended treatment is 
4 mg/kg of artesunate given once a day for three days and 25 mg base/kg of mefloquine.  
4.3.1.2.4 Artesunate + sulfadoxine-pyrimethamine 
This combination is distributed as 50 mg of artesunate, and tablets containing 500 mg of 
sulfadoxine with 25 mg of pyrimethamine. The total recommended treatment is 4 mg/kg of 
artesunate given once a day for three days and a single administration of sulfadoxine-
pyrimethamine (25/1.25mg base/kg) on day 1. 
4.3.1.2.5 Dihydroartemisinin+ piperaquine 
The 1
st
, 2nd and the 4 th combinations are commonly used in India. In a metaanalysis of the 
available 16 randomised controlled trials comparing artesunate to conventional treatment in 
falciparum malaria, artemisinin was found to hasten parasite clearance and decrease 
transmission potential(21).It was also found to decrease treatment failure rates and 
recrudescence. 
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4.4 MANAGEMENT OF SEVERE MALARIA 
Severe malaria is defined as malarial infection with presence of organ dysfunction or parasite 
index more than 5%. 
The organ involvement can be listed as follows: 
1) Metabolic acidosis 
2) Circulatory collapse/shock 
3) Acute respiratory distress syndrome/pulmonary edema 
4) Haemoglobinuria 
5) Anaemia 
6) Thrombocytopenia 
7) Acute kidney injury 
8) Acute liver failure/hepatic encephalopathy 
9) Hypoglycaemia 
10) Altered sensorium/seizures/cerebral malaria 
Presence of any one of the above mentioned organ dysfunction, is severe malaria. 
Severe malaria is managed by parenteral anti malarial mainly quinine or artemisinin based 
combination therapy. 
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4.5 EFFICACY OF ARTEMISININ 
The landmark trial ‗AQUAMAT‘ comparing quinine and artesunate in management of severe 
malaria in African children, showed favourable results for artesunate with 22.5% absolute 
risk reduction of mortality between groups, which was the primary outcome(22). Tolerance to 
artesunate was much better with no significant adverse effects when compared to quinine. 
The trial conducted in South east Asian population, recruiting 730 patients from India, 
Myanmar, Indonesia and Bangladesh ‗SEAQUAMAT‘ showed a 34.7% absolute reduction in 
the mortality in the artesunate group as compared to the quinine(23). 
Current evidence favouring artemisinin over quinine is from the published metanalysis in 
2012,which included 8 major randomised control trials including ‗Aquamat‘,‘Seaquamat‘ 
comprising of 1664 adults and 5765 children(24).In adults the relative risk for the outcome of 
death was found to be 0.64 over parenteral quinine and was found to be of statistical 
significance(24).The evidence was used by the World Health Organisation in 2010 to 
formulate the treatment guidelines in 2010,where parenteral artesunate is recommended as 
first line management of severe malaria(20). 
The recommended standard dosing regimen includes a 5 dose method which is 2.4 mg/kg at 
admission, 12 hours and 24 hours followed by once dosing everyday. Complications are to be 
managed appropriately. Therapy can be changed to oral once the patient tolerates or general 
condition shows an improving trend. 
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4.6 PHARMACOLOGY OF ARTEMISININ COMPOUNDS 
 
4.6.1 HISTORY OF ARTEMISININ COMPOUNDS: 
These compounds are derivatives of natural plant product, from the plant Artemisia annua 
and was discovered as early as 168 B.C(25).This was extracted and purified and was 
developed further as a drug by Chinese scientists. The potency was confirmed by animal 
studies and was demonstrable in nano molar concentrations. 
4.6.2 MECHANISM OF ACTION: 
Artemisinin belong to the endoperoxides,which is a potent antimalarial agent .They are 
classified as first and second generation compounds(26).The first generation is comprised of 
the natural product artemisinin as well as multiple other semi synthetic derivatives like 
artesunate and artelinate which are water soluble ,arteether and artemether are fat soluble 
derivatives .They belong to a broad class of sesquiterpene lactones, which contain the unique 
endoperoxide bridge, which is believed to cause the parasite destruction. The endoperoxide 
compound activates the formation of reactive oxygen species, which surpasses the parasite 
anti oxidant system and the intra erythrocytic free radicals produced by the host , leading to 
death of the parasite(27). 
The second postulated mechanism involves decomposition of the artemisinin compound in 
the presence of ferrous ion to from carbon centred free radical which reacts biochemically 
with the parasite and causes destruction(28). 
It has also been hypothesized that the artemisinin compounds form adducts with haemozoin 
present in the food vacuole of the parasite, which further leads to activation of artemisinin as 
a potent alkylating agent(29).This has been found to be augmented with addition of iron 
chelators like deferrioxamine.  
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The molecular target for artemisinin is SERCA – Sarcoendoplasmic reticulum calcium 
ATPase located in the pfATP6 locus of the Falciparum genome(30).After the activation of 
the compound by iron, the compound inhibits the pfATP6 which is outside the food vacuole, 
specifically the SERCA sequence, leading to parasite destruction.(30). 
4.6.3 PHARMACOKINETICS OF ARTEMISININ DERIVATIVES: 
Derivatives of artemisinin commonly used in clinical practice include: 
-Artesunate 
-Artemether 
-Dihydroartemisinin (DHA) 
The summary of the published data on pharmacokinetic parameters of artesunate and DHA 
post intravenous administration(31) are summarised in table 1 and 2. 
4.6.3.1 ARTESUNATE PHARMACOKINETICS 
The metabolism of artesunate occurs by esterase catalysed hydrolysis causing the formation 
of dihydroartemisinin, its potent metabolite. This process occurs very rapidly leading to rapid 
depletion of artesunate in the immediate post dose period. The average half life of  intra 
venous artesunate in the published studies was less than 15 minutes(31).It was also seen that 
there was liner dose response relation in doses from 0.8 mg/kg to 8 mg /kg(31). 
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EVIDENCE ON PHARMACOKINETICS OF IV ARTESUNATE 
REFERENCE SUBJECTS DOSE CMAX AUC 
Batty le et 
al,1998(32) 
12  adults with vivax 
malaria from Vietnam 
 
120 mg IV AS over 2 
min 
13685 876 
Batty,Thu et 
al,1998(33) 
26 adult uncomplicated 
falciparum malaria patients 
in Vietnam 
120 mg IV AS over 2 
min 
NA 1146 
Ilett et al,2002(34) 23 adults with 
uncomplicated  falciparum 
Malaria in Vietnam 
120 mg IV AS over 2 
min 
16146; 
16530 
1038; 
1230 
Newton et 
al,2006(35) 
17 adults with severe 
falciparum malaria in 
Thailand  
2.4 mg/kg IV AS over 2 
min 
130 49.2 
Li et al,2009(36) 30 healthy volunteers – 
phase I study 
 
0.5 mg/kg IV AS over 2 
mins 
1 mg/kg IV AS over 2 
mins 
2 mg/kg IV AS over 2 
mins 
 4 mg/kg IV AS over 2 
mins 
8 mg/kg IV AS over 2 
mins 
4797  
 
6128 
 
19420 
36100 
 
83340 
386 
 
593 
 
1595 
3038 
 
699 
Binh et al,2010(37) 17 healthy volunteers from 
Vietnam  
120 mg IV AS over 2 
min 
NA 846; 1269 
 
Table 1 – ARTESUNATE PHARMACOKINETICS [Adapted from 
Morris et al,Malaria Journal,2011](31) 
 
4.6.3.2 DIHYROARTEMISININ PHARMACOKINETICS: 
The metabolism of dihydroartemisinin is through the UDP glucoronyltransferase pathway, in 
particular UGT1A9 and UGT2B7(38).The esterase catalysed process of metabolism occurs 
slowly as compared to artesunate(31).The average half life as documented in the published 
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studies range from 18 minutes to 2.14 hours. Similar dose linearity as expressed by artesunate 
is also seen with dihydroartemisinin(31). 
EVIDENCE ON DIHYDROARTEMISININ PHARMACOKINETICS 
REFERENCE SUBJECTS DOSE CMAX AUC 
Batty le et al,1998(32) 12 adults with vivax 
malaria in Vietnam 
120 mg IV AS 
over 2 min 
2192 1845 
Batty Thu et 
al,1998(33) 
26 adult 
uncomplicated 
falciparum malaria 
patients in Vietnam 
120 mg IV AS 
over 2 min 
2648 2377 
Binh et al,2001(37) 17 healthy 
volunteers from 
Vietnam. 
120 mg IV AS 
over 2 min 
1507 NA 
Davis et al, 2001(39) 30 adults with 
falciparum malaria 
 
1: 12 with 
complications 
 
2: 8 without 
complications 
Group 1 & 2: 
120 mg IV AS 
over 2 min 
 
Group 3: 10 with 
moderately 
severe 
complications 
(240 mg IV AS 
infused over 4 
hours 
Group 1: 
2417 
Group 2: 
2531 
Group 3: 
910 
Group 1: 
2078 
Group 2: 
2559 
Group 3: 
5573 
Ilett et al,2002(34) 23 adults with 
falciparum malaria 
with no 
complications from 
Vietnam 
120 mg IV AS 
over 2 min 
2758,2730 2872,3298 
Newton 
et al,2006(35) 
17 adults with 
severe falciparum 
malaria in Thailand 
2.4 mg/kg IV AS 
over 2 min 
605 418 
Table 2 DIHYDROARTEMISININ 
PHARMACOKINETICS[Adapted from Morris et al, Malaria 
journal 2011](31) 
 
It has been proved without doubt that the maximum concentrations of artesunate is achieved 
post intravenous administration, hence it‘s utility in emergent management of severe malaria. 
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4.6.4 EFFECT OF INFECTION STATUS ON PHARMACOKINETICS: 
Population based pharmacokinetic studies have shown that the AUC and the peak 
concentrations of the drug level differ based on the severity and type of infection. Apart from 
the presence of food(for oral administration) and body weight, clearance of DHA was found 
to be lower on the first day of malaria when compared to day 3 of illness(40).Evidence also 
shows that the peak antimalarial activity is twice higher in the acute phase than the 
convalescent phase(41).But these were done on oral formulations and scarce data exists for 
intravenous formulations. 
4.7 HISTORY OF ANTIMALARIAL RESISTANCE 
The earliest evidence of anti malarial resistance dates back to the early 20 th century when 
resistance to chloroquine emerged in the ‗Greater Mekong‘ region, which was soon followed 
by sulphadoxine – pyrimethamine and mefloquine(42) 
4.8 ARTEMISININ RESISTANCE 
The first report of suspected resistance through delayed parasite clearance times was 
communicated to the world by Noedl et al(6) in the year 2008,which prompted further studies 
which provided an insight to this threat. Subsequent evidence by Dondorp et al(5) alerted the 
World Heath Organisation(WHO) to formulate and standardise case definitions to conduct 
therapeutic surveillance studies. 
Routine therapeutic surveillance is essential in malaria endemic regions to determine the 
parasite susceptibility patterns, and if required to revise the treatment policies based on the 
local sensitivity patterns. It is currently recommended by WHO, that regular studies be done 
once in 2 years, and if failure rates exceed 10% at day 28/day 42 of follow up, the treatment 
regimen has to be revised. 
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4.8.1 DEFINITION(43) 
 
The definition of artemisinin resistance depends on clinical and parasitological outcomes 
observed during routine therapeutic efficacy studies of ACTs and clinical trials of artesunate 
monotherapy: 
 an increase in parasite clearance time, as evidenced by ≥ 10% of cases with parasites 
detectable on day 3 after treatment with an ACT (suspected resistance) 
(Or)  
 treatment failure after treatment with an oral artemisinin-based monotherapy with 
adequate antimalarial blood concentration, as evidenced by the persistence of 
parasites for 7 days, or parasites being detected at day 3 and recrudescence within 
28/42 days (confirmed resistance) 
The latest development in this field is the identification of the novel mutation ―kelch -13‖ 
which is found to be signatory molecular marker of artemisinin resistance. Hence the 
definitions have been modified, taking this into consideration and the following has been 
proposed in the September 2014 update by WHO. 
4.8.2 SEPTEMBER 2014 UPDATE ON DEFINITION OF PARTIAL ARTEMISININ 
RESISTANCE(44) 
 
Suspected partial artemisinin resistance is defined as: 
-  ≥ 5% of patients carrying K13 resistance associated mutations 
(Or)  
- ≥ 10% of patients with persistent parasitemia after treatment with ACT /monotherapy 
with artesunate detected by microscopy on day 3. 
(Or) 
-  ≥ 10% of patients with a parasite clearance half life of ≥ 5 hours after  
treatment with ACT or artesunate monotherapy. 
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Confirmed partial artemisinin resistance is defined as: 
≥ 5% of patients with detectable Kelch 13 mutations, and other resistance associated 
mutations after treatment with ACT or artesunate monotherapy, to have either persistent 
parasitaemia by microscopy on day 3, or a parasite clearance half life of ≥ 5 hours. 
4.8.3 CLINICAL IMPLICATIONS OF DELAYED PARASITE CLEARANCE 
 
1) Failure to clear the parasites rapidly will compromise the care of patient in severe malaria 
2) It leads to prolonged exposure of the parasite to the partner drug leading to development of 
resistance to partner drug. 
4.8.4 EMERGENCE AND SPREAD OF RESISTANCE TO ANTIMALARIAL DRUGS 
 
The resistance of parasite develops as two parts: 
 In the first part, an initial genetic event produces a resistant mutant (de novo mutation), the 
genetic alteration gives the parasite a survival advantage against the drug.  
In the second part, the resistant parasites are selected and they replicate resulting in a parasite 
population that is no longer susceptible to treatment. 
4.8.5 FACTORS INFLUENCING DEVELOPMENT OF ANTIMALARIAL RESISTANCE 
 
 The frequency of genetic mutations. 
 The degree of resistance caused by the mutations 
 The resistance mechanism 
 The proportion of gametocytes/vectors exposed to the drug (selection pressure) 
 The  exposed number of parasites to the drug 
 The  concentration of the anti malarial drug to which the parasites are exposed 
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 The pharmacogenomics of the drug -  Individual dosing, duration, adherence – the 
variation and use in the community including the quality, availability, distribution and  
patterns of drug use 
 The  profile of the innate and acquired immunity of the person as well as the community 
 The  presence of detectable drugs in blood  to which the parasite is sensitive  
Poor quality of drugs is another important factor of major concern in South East Asia. 
Newton et al conducted an epidemiological investigation to identify the prevalence of fake 
artesunate in South east Asia(45).The study revealed 16 fake stickers on packages of the 
drugs manufactured, falsely identifying them as genuine. Chemical analysis revealed 
undetectable or extremely low levels of artesunate in those samples. There was significant 
adulteration with compounds such as paracetamol, older anti malarial drugs, minerals and 
antibiotics. This became further more apparent when a Burmese young gentleman succumbed 
to malaria with a PI of 5% despite having received the optimal dose of artesunate(46). 
India being a developing nation predisposes to unauthorised trades of pharmaceuticals across 
borders and distribution in areas with high endemicity, posing a serious threat of emergence 
of resistance secondary to exposure to sub therapeutic concentrations of artesunate. 
4.8.6 MONITORING ANTI MALARIAL DRUG EFFICACY AND DRUG RESISTANCE 
 
There are four major methods to assess anti malarial drug efficacy and to monitor emergence 
of resistance(47). 
1) Therapeutic efficacy studies 
2) In vitro tests 
3) Use of molecular markers 
4) Measurement of drug concentrations 
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Therapeutic efficacy studies are the current gold standard for determining antimalarial 
efficacy(4). 
4.8.7 GLOBAL PLAN FOR ARTEMISININ RESISTANCE CONTAINMENT 
 
The GPARC was established in response to confirmation of artemisinin-resistance in 
Cambodia and Thailand(5).This was initiated as a response to the emergence of resistance 
and to contain the spread of drug resistance malaria. 
The GPARC defined three areas of artemisinin resistance: 
TIER I – areas where confirmed evidence of artemisinin resistance has been documented, 
where an immediate, team based response is recommended to contain or eliminate resistant 
parasites. 
TIER II - areas with movement of mobile and migrant populations from tier I areas or shared 
borders with tier I areas, with strict and vigilant malaria control to reduce 
transmission and/or limit the risk of emergence or spread of resistant parasites. 
TIER III - P. falciparum endemic areas where there is no evidence of artemisinin resistance 
and have the contact with tier I areas is limited, where prevention and increasing coverage 
with parasitological diagnostic testing, quality-assured ACTs and vector control is required. 
4.8.8 SUMMARY OF ARTEMISININ RESISTANCE IN GREATER MEKONG REGION 
 
The pioneer trial which identified prolonged fever and parasite clearance times in South east 
asia,mainly in Pailin of western Cambodia and the north western Thai Cambodian Border 
published by Dondorp et al(5),attracted the world‘s attention, to the serious threat of resistant 
malaria. Since then containment efforts and research are underway to stop the spread of 
resistance as well as to work towards elimination of the disease. 
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Currently the Greater Mekong region is the epicentre of artemisinin resistance. The 
proportions of patients with detectable parasitemia on microscopy at 72 hours (day 3), is the 
early sign to indicate emergence of artemisinin resistance(48). 
 
Figure 7 Sites of confirmed resistance to artemisinin 
[Adapted from ‘Emergency response to artemisinin resistance in Greater 
Mekong Sub region WHO 2013](49) 
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The summary of data on day 3 parasitemia rates and treatment failure rates have been 
summarised in the table: 
 
Figure 8 Status report on artemisinin resistance 2014 
 
4.8.9 SPREAD OF ARTEMISININ RESISTANCE 
 
An international multicentre randomised controlled trial was conducted at 15 sites in 10 
countries, including 4 sites in Cambodia,3 sites in Thailand, Laos, Vietnam, Myanmar, 
Bangladesh, India,Nigeria,Kenya and Democratic republic of Congo(50). 
 Prolonged parasite clearance was seen in western Cambodia and eastern Thailand with 
parasite clearance half-life more than 5 hours (49 to 73%).The same was noted to be 14 to 
28% in northern Cambodia, Vietnam, and eastern Myanmar, and very low proportions in 
other centres. 
Resistance is now viewed as sequelae of widespread use of this drug and the rates of spread 
are accentuated by the socio economic conditions in different geographic regions(51). 
The way to curb the spread of resistance is to conduct more surveillance in areas where the 
resistance rates are unknown. Second major intervention is to discourage artesunate 
monotherapy, which is a prevalent practice in private sectors in South East Asian countries. 
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4.8.10 KELCH 13 PROPELLER POLYMORPHISM – SIGNIFICANCE 
 
A molecular marker has been identified to monitor the spread of resistance ,which is a 
sequelae of mutations in portions of P.falciparum gene (PF3D7_1343700) encoding Kelch 
(K13) propeller domains(52,53).A team of international scientists produced an artemisinin-
resistant parasite line by exposing the artemisinin sensitive parasite to incremental doses of 
artemisinin over a period of 5 years. This developed resistant clone was whole-genome 
sequenced with comparison to the parental sensitive clone. 
Seven new genes containing eight mutated single nucleotide polymorphisms were identified 
in the resistant clone. These mutations were compared with the genotypes found in 
Cambodian – Thailand borders, which to further identification of mutations in the propeller 
domain of the kelch protein K13.This is the signatory molecular maker of artemisinin 
resistance. 
This will help in the characterization of artemisinin resistance at molecular level and also 
assists in monitoring of the spread of artemisinin resistance in the community. The P. 
falciparum cysteine protease falcipain-2 (FP2; PF3D7_1115700) has also been shown to 
contribute to mechanism of action of artemisinin. A stop mutation has also been identified in 
the FP2 gene which was subsequently noted on sequencing the parasites in patients with 
delayed clearance(53). 
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Figure 9 Current global scenario of artemisinin resistance 
[Adapted from The New England Journal of Medicine(7)] 
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5. METHODS 
 
5.1 SAMPLE AND SETTING 
 
The study was conducted between October 2012 and June 2014 at CMC, Vellore. Patients presenting 
with acute febrile illness, diagnosed to be malaria, fulfilling the inclusion criteria and willing to 
participate in the study were included into the study. This included hospitalised patients with malaria 
as well as patients attending the emergency department and the General medicine outpatient clinic. 
The study and the research procedures were fully explained to the participants and those who gave 
written consent were allowed to participate in the study. The consent was obtained in the regional 
language that the patient/relative was conversant (Annexure 1) 
5.2 STUDY DESIGN 
 
This is a prospective cohort study done in patients with malaria, assessing the treatment 
response to artemisinin combination therapy. 
5.3 SAMPLE SIZE 
 
The sample size required to show an incidence of treatment failure to artemisinin 
combination therapy as 25% with 10 % precision was calculated by using the formula: 
4pq/d
2
.This was found to be 75. 
5.4 PARTICIPANTS 
 
The participants in this study fulfilled the following inclusion criteria: 
1) Age between 15 years to 60 years;  
2) P. Falciparum infection alone or a mixed infection as detected by microscopy 
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3) Detectable asexual forms in peripheral smear with minimal detectable parasite index of 
0.1% 
4) Presence of axillary temperature ≥ 37.5 °C or oral or rectal temperature of ≥ 38 °C  or 
history of fever during the past 24 hours. 
Presence of causes other than malaria for the fever, were excluded. 
5.5 MEASUREMENTS – DATA COLLECTION 
 
The data collection was done in data abstraction forms (Annexure 2) by the principal 
investigator of the study at the first visit, day 2, day 3 and day 7. 
The following details were recorded specifically: 
1) Demographics – Age, sex, geographic location, occupation and history of travel to malaria 
endemic area. 
2) Duration of symptoms 
3) Clinical assessment details – vital signs, systemic examination 
4) Presence and duration of complications 
5) Laboratory parameters including haematological and biochemical tests. 
5.5.1 BODY TEMPERATURE 
 
Axillary temperature was measured at baseline (day 0 before dosing) and on days 1, 2, 3 and 
day 7 or till discharge whichever was earlier till defervescence. 
Temperature was measured with a thermometer that has a precision of 0.1 °C. Temperature 
was measured as clinically indicated. If the result is < 36.0 °C, the measurement was 
repeated. The same route was used throughout the study. 
In outpatients, they were advised to manually record their temperature (under supervision by 
an health care professional), till defervescence. 
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They were followed up every day till first 3 days and on day 7 with temperature charting. 
5.5.2 MICROSCOPIC BLOOD EXAMINATION FOR MALARIAL PARASITES 
Blood samples for malarial parasites were collected twice daily from the patients, till the 
clearance of asexual ring forms from peripheral smears. 
The peripheral blood was centrifuged to obtain the quantitative Buffy coat (QBC) and was 
examined for the presence of malarial parasites. If present, thick and thin smears were done 
in the sample to identify the species in order to confirm adherence to the inclusion criteria.  
Parasite density was recorded in terms of parasite index. The parasite index was calculated in 
the smear by counting the number of parasitized red blood cells per 1000 red blood cells. 
This procedure was repeated every 12 hourly till disappearance of asexual ring forms in the 
QBC.The minimum value of parasite index was 0.1%. 
 5.5.3 ANTI MALARIAL ARTESUNATE – DIHYDROARTEMISININ  BLOOD 
CONCENTRATION 
Anti malarial blood concentrations were measured in patients on intravenous artesunate for 
severe malaria. Hospitalised consecutive patients who fulfilled the following inclusion 
criteria were included for the pharmacokinetic assessment studies of artesunate. 
 Hospitalised patients on Intravenous artesunate.  
 The timing of dose 3 is in the normal course after obtaining the results of the 
peripheral smear.    
 Patients who fulfil the criteria for early treatment failure (asexual ring stages 
positive on day 3) and those having adequate therapeutic response were 
included for pharmacokinetic assessment. 
 Willingness to participate in the study 
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The samples were collected by the principal investigator in the clinical pharmacology unit. 
The patients were fasting prior to the procedure, only sips of fluid were allowed prior to the 
procedure. 
A 23 gauge insyte (peripheral venous line) was inserted into the cubital vein of the opposite 
arm to which the IV drug (Artesunate) was administered. 
Venous blood specimens of 2 ml each was collected at trough, 5, 7, 9,15, 30, 45, 60, 90 min, 
120 and 240 minutes  post dosing with intravenous artesunate. 
5.5.3.1 DEVELOPMENT OF DRUG ASSAY – ARTESUNATE AND DIHYDRO 
ARTEMISININ 
The instrument used for the assay – ‗ACQUITY UP/LC – MS/MS‘ 
COLUMN - Phenomenex Luna 5u PFP, diameter 50* 2 mm 
MOBILE PHASE – A – 2 m mol ammonium acetate buffer in water + 0.1% formic acid 
                                 B – Acetonitrile + 0.1 % formic acid 
GRADIENT            
Time(mins) Flow(ml/min) % A % B Curve 
 0 0.4 80 20  
0.5 0.4 30 70 6 
2 0.4 80 20 11 
 
The flow was stopped at 3 minutes. 
COLUMN TEMPERATURE – 35 deg C 
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EXTRACTION PROCEDURE: 
- 100 ml of plasma sample was taken. 
- 400 micro litre of acetonitrile containing internal standard (Artemisinin-40 ng/ml) was 
taken. 
- The vertex was set at 1 minute. 
- This was centrifuged at 13000 rpm for 5 minutes. 
- The supernatant was separated and 20 micro litre was injected into the column. 
MRM FILE (MULTIPLE REACTION MONITORING) 
Compound name Parent mass Daughter 
mass 
Dwell time Cone 
voltage 
Collition 
voltage 
Artesunate 402.24 267.29 0.1 15 10 
Dihydroartemisinin 302.1 267.1 0.1 12 8 
Internal 
standard(artemisinin) 
300.08 209.4 0.1 13 12 
 
MS TUNE PAGE 
Capillary (kV) – 4 
Cone (V) – 20 
Extractor (v) – 2 
RF Lens (v) – 0.4 
Source temperature (deg C) – 100 
Desolvation temperature (deg C) – 400 
Desolvation gas flow (l/hr) – 800 
Cone gas flow (l/hr) – 50 
Collition gas flow (ml/min) – 0.16 
Plasma concentrations of artesunate and dihydroartemisinin (the active metabolite of 
artesunate) were measured by means of high - throughput liquid chromatography -tandem 
mass spectrometry, (LC-MS/MS) in the Clinical Pharmacology Unit.  
The AUC (Area under curve), and other pharmacokinetic parameters as Cmax (Maximum 
concentration), trough, clearance was calculated.  
The pharmacokinetic parameters between the two categories of patients were compared for 
any significant statistical difference. 
The dose response relationship and the clinical outcomes were correlated through logistic 
regression (uni and multivariate) analysis 
5.6 SAMPLES FOR IDENTIFICATION OF MOLECULAR MARKERS 
 
Samples were collected from the patients enrolled into the study (Minimum – 1 and 
maximum of 3). 
They were allowed to stand and the blood clot and serum were separated. 
All the samples are stored in the Wellcome laboratory at -90 deg C for future studies on 
identifying the genetic markers of artemisinin resistance. 
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6. OUTCOMES 
 
The following parameters were specifically assessed in this study. 
6.1 PRIMARY OUTCOMES 
6.1.1 Parasite clearance time - as assessed by microscopy.  
The parasite clearance time was defined as the time from the start of treatment until the first 
negative blood smear. 
6.1.2 Fever clearance time – as assessed by clinical methods. 
The fever clearance time was defined as the time taken for temperature to fall below 37˚C 
and remain there for at least 24 hours. In other words, it was the time to the first temperature 
reading of less than 37.5°C and the time to the start of the first 24-hour period during which 
the temperature remained below 37.5°C. 
6.1.3Gametocytemia in patients - Proportion of patients with gametocytemia before, during and 
after treatment with artesunate, assessed at admission, on days 3, 7 stratified by presence of 
gametocytes at enrolment. 
Treatment outcomes were classified based on WHO guidelines for surveillance of anti 
malarial efficacy(47)  
6.2 Early treatment failure (ETF): 
- Danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitemia; 
- Parasitemia on day 2 higher than on day 0, irrespective of axillary temperature; 
- Parasitemia on day 3 with axillary temperature ≥ 37.5 °C;  
- Parasitemia on day 3 ≥ 25% of count on day 0 
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6.3 Late clinical failure (LCF) 
- Danger signs or severe malaria in the presence of parasitaemia on any day between day 
4 and day 28 (day 42) in patients who did not previously meet any of the criteria of early 
treatment failure;  
- Presence of parasitaemia on any day between day 4 and day 28 (day 42) with axillary 
temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of 
early treatment failure. 
6.4 Late parasitological failure 
- Presence of parasitaemia on any day between day 7 and day 28 and axillary temperature 
< 37.5 ºC in patients who did not previously meet any of the criteria of early treatment 
failure or late clinical failure. 
6.5 SECONDARY OUTCOMES: 
 
1) Comparison of the pharmacokinetics of artesunate and the metabolite dihydroartemisinin 
in patients with and without treatment failure, following initiation of artemisinin combination 
therapy (ACT) and comparison with the clinical and parasitological outcomes. 
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7. DATA ANALYSIS AND 
STATISTICAL METHODS 
 
Data entry was done by the principal investigator in Microsoft Excel Spreadsheet 
(Annexure 4). 
The results were analysed using SPSS software version 16. 
The parasite clearance and fever clearance times were plotted against time and were 
assessed using the Kaplan Meier methods and the median clearance times were obtained. 
Data was analysed by the student t test, chi square test or Mann Whitney U test, Fisher‘s 
exact test based on the normality of distribution of the variables. 
The pharmacokinetic studies were analysed manually and the AUC was calculated for 4 
hours exposure using the trapezoidal rule. The trapezoidal rule consists of dividing the 
plasma concentration-time profile into several trapezoids and calculating the AUC by 
adding the area of these trapezoids. The statistical correlation was obtained through 
Wilcoxon signed rank test and Mann Whitney U tests as applicable. 
Univariate analysis was done to identify the factors which might be associated with delayed 
fever and parasite clearance times. The factors identified to show association were included 
in the multivariate analysis and the logistic regression models, to derive the odds ratio and 
measure the statistical significance. 
The factors with which showed a trend towards association were included in boot strap 
analysis to generalize the finding to the parent population in a scientific manner to derive 
the degree of association  
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8. FUNDING AND APPROVAL 
 
8.1 Funding Source 
 
A FLUID Research grant (Institutional grant) was approved for the purpose of this study. 
The funds were used for the development of the artesunate and dihydroartemisinin LC – 
MS/MS assay and for processing of the samples, procurement of reagents and the pure 
samples. 
 8.2 Institutional Research Board approval and ethical considerations 
The research proposal was discussed by the Institutional Review Board in October 2012 and 
approval was obtained [IRB Min. No.8056 dated 06.11.2012]. 
 There were no ethical issues related to this study. Institutional review board approval was 
obtained for the procedures for the pharmacokinetic studies, prior to the commencement of 
the study (Annexure 5)             
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9. RESULTS 
 
The study was conducted prospectively over a period of 20 months (October 2012 – June 
2014) in the Department of Medicine, in the inpatient wards, emergency department and the 
outpatient departments in Christian Medical College,Vellore,a tertiary care centre in South 
India.  
Clinical assessment included detailed history and physical examination was done on day 1, 2, 
3 and 7 days. All the haematological and biochemical tests done and the parameters were 
noted in the Data abstraction forms (Annexure 5).  
Patients with acute febrile illness, diagnosed as malaria, 15 years and above, who fulfilled the 
inclusion criteria were enrolled into the study. 
Fifty four patients fulfilled the inclusion criteria and were included into the study. 
All participants provided written consent to participate in the study, and 17 patients were 
enrolled into the pharmacokinetic studies of Intravenous artesunate following informed 
consent. 
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9.1 STUDY FLOWCHART 
 
 
 
PATIENTS PRESENTING WITH ACUTE FEBRILE ILLNESS  
 
 
 
PERIPHERAL SMEARS POSITIVE FOR MALARIAL PARASITES 
 
 
 
INFECTION WITH PLASMODIUM FALCIPARUM/MIXED INFECTION (N = 54) 
                                                   
 
   
 
 
 
 
 
 
 
 
 
 
EXCLUSION,* 
Infection with Plasmodium vivax (excluded 
from further evaluation) 
COMPLETED FOLLOWUP – 
DAY 7 
                      (N = 54) 
INCLUDED FOR PHARMACO – KINETIC 
STUDIES (N = 17) 
                     (N = 17)  
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9.2 BASELINE CHARACTERISTICS OF THE POPULATION 
9.2.1 DEMOGRAPHIC CHARACTERISTICS 
 
 A total of 54 adult patients more than 15 years of age, with peripheral smear positive for 
Plasmodium falciparum were evaluated.  
The mean age (+_SD) was 37.59(14.147) with a range of 17 - 75 years.  
The distribution of cases yearly and the time trends are summarised in Figure 10 and 11 .The 
number of cases were similar in 2012 and 2013,but the number of patients were distributed 
throughout the last 6 months in 2013,compared to 2012,when the peak was during October – 
December, corresponding to the monsoon season.  
There was significant male preponderance (Figure 12). 46.3% were unskilled workers 
predominantly agricultural labourers followed by 25.9% being in the professional category, 
residing in places with malaria endemicity during the monsoons like Chennai (Figure 13).  
The patients were mainly from the two states of Tamil nadu and Andhra Pradesh, with 57.4% 
in the former and 38.9% in the latter group.  
Majority of the recruited patients were hospitalised inpatients (81.5%). 
The history of travel to malaria endemic regions (Chennai, Chittoor and other pockets in 
Andhra Pradesh) was elicited in 37% of the patients. 
33.3% had mixed malarial infection with falciparum and vivax species. 
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Figure 10 – Year wise distribution of malaria cases 
1 -2012, 2 – 2013 ,3 - 2014 
 
Figure 11 - Case distribution throughout the period of recruitment 
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Figure 12- Sex distribution  
(1 – Male, 2 – female) 
 
Figure 13 - Occupation 
 
Professional(14) 1 
skilled labourer(12) 2 
Unskilled(25) 3 
Unemployed(3) 4 
9.2.2 PROFILE OF COMORBID ILLNESS 
 
The percentage of co morbid illness was low, probably in view of the low mean age of the 
cohort, details are summarised in Table 3. 
Variable Number % Comments 
Hypertension 
Present 
Absent 
 
3 
51 
 
5.6 
94.4 
 
Chronic Kidney 
Disease 
Present 
Absent 
 
0 
54 
 
0 
100 
 
CerebroVascular 
Accident 
Present 
Absent 
 
0 
54 
 
0 
100 
 
Chronic Liver 
Disease 
Present 
Absent 
 
1 
53 
 
1.9 
98.1 
One patient had 
Hepatitis B related 
chronic liver disease 
Diabetes Mellitus 
Present 
Absent 
 
4 
50 
 
7.4 
92.6 
The median age of 
the diabetics were 
46(40 – 56) 
Ischemic Heart 
Disease 
Present 
Absent 
 
3 
51 
 
5.6 
94.4 
All of the three 
patients had 
underlying diabetes 
and hypertension 
HIV Co – infection 
Present 
Absent 
 
0 
54 
 
0 
100 
 
Chronic Obstructive 
Pulmonary disease 
Present 
Absent 
 
 
0 
54 
 
 
0 
100 
 
 
Table 3 Profile of co morbid illnesses 
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9.2.3 SUMMARY OF CLINICAL SYMPTOMS 
 
The most common presenting symptom was fever which was present in all the patients. The 
median duration of fever prior to presentation was 7 days with minimum of 4 days to 
maximum of 60 days. 61.1% reported jaundice as defined yellowish discolouration of skin, 
mucous membranes or high coloured urine. 27.78% reported breathing difficulty or chest 
tightness at presentation .Altered sensorium was present in 24.07% which included 
drowsiness, decreased verbalisation or irrelevant speech, inadequate response to call or 
commands. 2 patients had seizures at presentation, both of which were generalised tonic 
clonic convulsions requiring anti epileptic therapy. Of the bleeding manifestations, 6 patients 
reported haematuria, 4 patients had haematemesis suggestive of upper GI bleed and 2 patients 
reported epistaxis.The findings are summarised in Figure 
14
 
Figure 14 - Summary of clinical symptoms at admission 
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9.2.4 SUMMARY OF CLINICAL SIGNS 
 
Fever was present in all patients (n = 54).Clinically evident icterus was present in 61.1%.As 
evident the mean values of the cohort indicate the presence of systemic inflammatory 
response syndrome. Hypoxia was not a common finding (n=5), though 27.78% reported 
symptoms of respiratory distress. The summary of findings is presented in table 4. 
Summary of clinical signs at admission 
Variable Mean SD Minimum Maximum 
Pulse Rate(/min) 108.89 19.187 68 170 
Respiratory rate(/min) 25.34 8.218 14 50 
Temperature(degF) 101.460 1.9635 95.7 105 
Systolic blood pressure(mm Hg) 98.91 23.565 0 160 
Diastolic blood pressure(mm 
Hg) 
61.32 61.32 0 90 
Pulse oximetery (%) 95.43 4.294 80 99 
GCS score 14.32 2.017 3 15 
 
Table 4 – Summary of clinical signs at admission 
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9.2.5 SUMMARY OF SYSTEMIC EXAMINATION 
 
The most common systemic examination finding was that of hepatomegaly, followed by 
hepatosplenomegaly, which was evident in 86.74%. 4 patients had meningeal signs positive, 
however patients were not subjected to CSF analysis in view of abnormal coagulation 
parameters.10 patients who reported respiratory distress at presentation, had bilateral 
crepitations but with no other features to suggest a cardiac dysfunction.2 patients had 
evidence of bilateral pleural effusion, on diagnostic aspiration was found to be transudative 
effusion. The summary of findings are summarised in Table 5. 
Summary of systemic examination at admission 
Variable Number % Comments 
Cardiovascular 
examination 
Normal 
Abnormal 
 
 
51 
3 
 
 
94.34% 
5.66% 
3 patients had Ischemic 
heart disease with 
moderate LV 
dysfunction. 
Respiratory 
examination 
Normal 
Abnormal 
 
 
40 
14 
 
 
73.5% 
26.41% 
The most common 
finding was tachypnea. 
10 patients had bi-basal 
crepitations. 
2 patients had bilateral 
pleural effusion. 
5 patients had Hypoxia. 
Abdominal 
examination 
Normal 
Abnormal 
 
 
8 
46 
 
 
13.20% 
86.74% 
 
The most common 
finding was 
hepatomegaly, 
followed by 
hepatosplenomegaly. 
3 patients had evidence 
of free fluid. 
CNS examination 
Normal 
Abnormal 
 
41 
13 
 
75.4% 
24.52% 
The most common 
finding was 
drowsiness. 
4 patients had terminal 
neck stiffness. 
 
Table 5 – Summary of systemic examination at admission 
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9.2.6 SUMMARY OF LABORATORY INVESTIGATIONS: 
 
9.2.6.1 Haematological parameters: 
 
Anaemia was noted in 51.8% of the patients with mean haemoglobin of 10.9 gm/dl. 27.7 % 
(n=15) required transfusion of blood products – commonly packed cells. 3 patients required 
multiple units of fresh frozen plasma (mean – 4) and cryoprecipitate (mean – 12).The mean 
leucocyte counts were within normal limits with no significant left shift. 
 92.4% of the patients had thrombocytopenia, which was found to be the most common 
haematological abnormality. The coagulation parameters were available for 11 patients, and 
derangement of activated partial thromboplastin time was noted. Fibrinogen was done in 2 
patients who presented with overt systemic bleed requiring intensive care. Both the patients 
had underwent gastroscopy and colonoscopy which showed features of diffuse mucosal 
bleed. This was summarised in Table 6. 
Haematological parameters at admission 
Variable Mean SD Minimum Maximum 
Haemoglobin(gm/dl 10.956 2.8121 4.1 15.4 
Total leucocyte counts(cu mm) 6581.48 4047.13 1400 27200 
Neutrophil count (%) 62.80 16.808 8 95 
Lymphocyte count 25.24 14.02 3 79 
Platelets(/cu mm) 56245.28 45770.290 6000 237000 
Prothrombin Time(seconds) 13.83 2.227 11 17 
INR 1.2650 0.196 1.02 1.52 
Activated partial thromboplastintime(secs) 33.891 7.4923 23 48.8 
Fibrinogen 196.150 133.1482 102 290.3 
Table 6 – Haematological parameters at admission 
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9.2.6.2 Biochemical parameters: 
 
Among the metabolic derangements, acute liver injury was the most common biochemical 
abnormality and was seen in 75.9 %( n= 41).Hyperbilirubinemia, predominantly 
unconjugated hyperbilirubinemia was seen. There was significant transaminitis noted in all 
patients with SGOT being more than SGPT.  
Hyponatremia was seen in 64.8 %( n = 35) and hypokalemia in 20.37 %( n = 11).The most 
common acid base abnormality was metabolic acidosis which was seen in 72.22 %( n = 39). 
Acute kidney injury was seen in 53.70 %( n = 29), with 55% having prerenal azotemia. 
Blood glucose levels were available at presentation for 42 patients. Of them 6 patients had 
documented hypoglycaemia and 3 had hyperglycaemia. 
Serum lactate dehydrogenase levels were available for 15 patients, which showed very high 
levels indicating the destruction caused by parasites to the red blood cells. 
Procalcitonin was done in 4 patients who presented in shock, which showed a mean value of 
108.92 indicating severe sepsis. 
Cardiac biomarkers were available for 2 patients who were seriously ill with multi organ 
dysfunction requiring intensive care. The mean troponin T levels were elevated indicating a 
component of sepsis related myocardial dysfunction.  
The findings are summarised in table 7. 
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Biochemical parameters at admission 
Variable Mean SD Minimum Maximum 
Sodium(m mol/dl) 131.89 5.882 109 143 
Potassium(m mol/dl) 4.05 0.632 3 6 
Bicarbonate 19.15 5.342 4 29 
Urea(mg/dl) 65.16 66.094 13 306 
Creatinine(mg/dl) 1.7006 1.3605 0.57 6.54 
Ph 7.3128 0.195 6.80 7.54 
Procalcitonin 108.922 88.089 36.14 233.50 
Total Bilirubin(mg/dl) 5.291 6.0282 0.6 27 
Direct Bilirubin (mg %) 3.508 5.114 0.2 20.5 
Total protein(gm/dl) 6.281 0.8714 4.8 8.1 
Albumin(gm/dl) 3.130 0.6423 1.9 4.5 
SGOT(U/l) 65.32 62.294 18 368 
SGPT(U/l) 36.34 29.421 6 158 
Alkaline phosphatase(U/l) 94.28 38.53 31 221 
Glucose(mg/dl) 115.93 47.082 66 342 
Lactate dehydrogenase(U/l) 1827.90 1081.16 132 4014 
Creatine phosphokinase(mg/dl) 158.60 141.023 30 493 
CK – MB 7.96 4.822 4.55 11.37 
Troponin - T 141.06 130.58 48.72 233.40 
 
Table 7 – Biochemical parameters at admission 
 
9.2.7 SEVERITY OF MALARIA 
 
74% of the cohort fulfilled the definition of severe malaria by the World Health 
organisation.Involvment of any organ system is considered as severe malaria. 
26% had uncomplicated malaria. This summarised in Figure 15. 
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Figure 15: Severity of Malaria 
1-Severe malaria, 2 – Uncomplicated malaria 
 
9.2.7 TREATMENT REGIMEN 
 
51.8% of the enrolled population received Intravenous artesunate with doxycycline 
(n=28).14.8% received oral artemether with lumefantrine (n = 8).25.92% received 
intravenous artesunate with doxycycline, which was subsequently changed over to oral 
artemether and lumefantrine (n = 14). 
5 patients were given artesunate with clindamycin as rescue therapy, in view of treatment 
failure with artesunate and doxycycline. 11 patients received empirical broad spectrum 
antibiotic therapy in addition to ACT.Piperacillin – tazobactem was the commonest broad 
spectrum antibiotic used. 
9.2.8 REQUIREMENT OF DIALYSIS 
 
4 patients out of 54 required dialysis support in view of oliguric acute kidney injury with 
severe metabolic acidosis and hyperkalemia. 1 patient in addition to the above mentioned 
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indication required the same for hyperparasitemia with parasite index of 58%.The average 
duration of dialysis requirement was 3 days. 
 
9.2.9 REQUIREMENT OF VENTILATORY SUPPORTS 
 
40.7% of the patients in the cohort required oxygen therapy.4 patients required non invasive 
ventilation.4 patients required invasive mechanical ventilation, the most common indication 
being severe metabolic acidosis with encephalopathy. The duration of ventilatory support 
requirement ranged from 1 day to 7 days.1 patient had cerebral malaria complicated by 
hypoxic brain damage, hence underwent tracheostomy, indication being failure to wean off 
ventilation. 
9.2.10 MORTALITY 
 
2 patients died after recruitment in the study. 1 patient died in the emergency department due 
to refractory shock with severe acidosis. The other patient was admitted in intensive care unit, 
with severe metabolic acidosis, multi organ dysfunction syndrome in shock. He died 12 hours 
post admission, secondary to refractory acidosis and shock. 
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9.3 PRIMARY OUTCOMES 
 
The mean parasite index at admission was 5.51 %( 0.1% – 48%: SD – 11.4).The mean 
temperature at admission was 101.4 F. 
9.3.1 PARASITE CLEARANCE TIME 
 
Parasite clearance times were calculated for 51 patients. 3 were excluded as they did not have 
any detectable asexual ring forms in the peripheral smear. 
25.5 %( n = 13) had delayed parasite clearance time of more than 48 hours (asexual ring 
stages seen in peripheral smear on day 3 of ACT). The mean estimate of the parasite 
clearance time was 43.049 hours (95% CI: 33.9 – 52.2).The median parasite clearance time 
was estimated to be 36 hours (95%CI: 27.08 – 44.91). Among the patients with delayed 
parasite clearance (n = 13), the mean clearance time was found to be 77.53 hours. 
The cumulative parasite clearance curve - figure 16 
 
Figure 16 – Parasite clearance curve 
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9.3.2 FEVER CLEARANCE TIME: 
 
Fever clearance times were calculated for 54 patients. 16.7% of patients had delayed fever 
clearance time (n = 9).The mean fever clearance time was 40.29 hours (95% CI: 27.78 – 
52.81).The median fever clearance time was estimated to be 24 hours (95% CI: 18.69 – 
29.30).Among the patients with delayed fever defervescence, the mean fever clearance time 
was 84.6 hours. 
 5 patients had relapse of fever after a period of defervescence.The mean duration of afebrile 
period after which they relapsed was 24 hours. The mean clearance time following relapse 
was 54 hours. 
The cumulative fever clearance curve – figure 17 
 
Figure 17 – Fever clearance curve 
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9.3.3 GAMETOCYTE CLEARANCE TIME 
 
The mean gametocyte clearance time was estimated to be 5.4(1 – 19) days. The proportion of 
patients with gametocyte positivity on day 0, 3,7,14 are summarised in Figure 17.  
The median gametocyte clearance time was 7 days (range: 3 -19) for patients with delayed 
clinical and parasite clearance times when compared to 3.5(range: 1 – 14) days in patients 
with adequate clinical and parasitological response. However this parameter might have been 
underestimated because the gametocyte clearance was assessed only up to day 7.If the 
patients were hospitalised more than day 7 ,they were followed up to discharge. 
 
Figure 18 - Proportion of patients with detectable gametocyte vs. the 
days post ACT. 
1 – Day 1, 2 – Day 3, 3 – Day 7, 4- Day 14 
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9.3.4 SUMMARY OF TREATMENT OUTCOMES 
 
The proportion of patients with early treatment failure(47)defined as persistent parasitemia on 
day 3 of ACT was 25.5%. 
9.3 %( n = 5) of the patients had relapse of fever post treatment for 7 days with ACT, 
suggestive of recrudescence. However they did not fulfil the criteria for late 
clinical/parasitological failure. 
As per the updated definition of artemisinin resistance – August 2014(44),the proportion of 
patients fulfilling the criteria for partial artemisinin resistance was 25.5%. 
9.4 PHARMACOKINETIC STUDIES OF INTRAVENOUS ARTESUNATE (n = 17)  
 
The pharmacokinetic studies were done for patients hospitalised with malaria on IV 
artesunate. 
The study was done on day 3 of initiation of artemisinin combination therapy. 
The assay for measurement of drug levels was developed by the department of Clinical 
Pharmacology. 
The number of patients recruited for the same following informed consent was 17. 
2 patients were excluded from the analysis in view of different time points used for the 
sample collection.  
The mean dose used in the patients was 2.4 mg/kg. The details of sampling and techniques 
are described in detail in the methodology section. 
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The maximum concentrations of artesunate and dihydroartemisinin, the time to peak 
concentrations, the levels of 4 hour drug exposure and the clearance of the drug were 
characterised.  
The parameters were compared between patients with adequate clinical and parasitological 
response (n = 11) and delayed parasite clearance (n = 5), and statistical methods were used to 
ascertain significance.  
There were no serious adverse effects noted with administration of the drug. 
9.4.1   Baseline characteristics of intravenous artesunate 
 
The mean maximum concentration attained by artesunate was 5815.03 ng/ml. It followed a 
linear dose relationship. The minimum level was 1878.36 ng/ml and the maximum level 
attained was 11989.97 ng/ml. The peak artesunate concentration was reached in 5 minutes. 
The rapid metabolism of the compound is evident with the rate of clearance of the drug, 
calculated by the formula (dose/AUC) which was 5.085 litre/kg/hour. This is summarised in 
table 8. 
Pharmacokinetics of Intravenous artesunate 
Variable Mean Median Range(min – max) SD 
Maximum drug concentration(ng/ml) 
 Cmax 
5815.033 5867.50 (1878.36 - 11989.97) 2973.36 
Time to maximum concentration(mins)  5 5 -   
- 
AUC( 0 – 4 hr exposure) 649.001  650.45 (204.67 – 1220.65) 321.66 
Clearance(l/kg/hr) 5.085  -   -  2.725 
 
Table 8 – Pk parameters of Intravenous Artesunate 
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9.4.2 Baseline characteristics of Dihydroartemisinin – Metabolite of Artesunate 
 
Dihydroartemisinin is the active metabolite of artesunate.  
The mean maximum concentration attained by dihydroartemisinin was 658.53 ng/ml.  
It followed a linear dose relationship.  
The minimum level was 180.09 ng/ml and the maximum level attained was 1274.13ng/ml. 
The peak dihydroartemisinin concentration was reached in 12 minutes, probably the time 
taken for artesunate to completely metabolise to dihydroartemisinin. 
The rate of clearance of the drug, calculated by the formula (dose/AUC) was 3.77 
litre/kg/hour.  
The findings are summarised in Table 9. 
 
Pharmacokinetics of Dihydroartemisinin 
VARIABLE Mean  Median  Range (min – max) SD 
Maximum drug concentration(ng/ml) 
 Cmax 
658.53 573.53 (180.09 – 1274.13) 345.66 
Time to maximum 
concentration(mins) 
 12 12 -  - 
AUC( 0 – 4 hr exposure) 1053.55 884.80 (213.81 – 2654.84) 712.94 
Clearance(l/kg/hr) 3.77  -   -  - 
 
Table 9 – Pk parameters of Dihydroartemisinin 
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9.4.3 Pharmacokinetic parameters of artesunate and DHA among patients with 
adequate clinical and parasitological response 
The pharmacokinetics of artesunate and dihydroartemisinin levels is tabulated for the patients 
with adequate clinical and parasitological response (Table 10).  
The peak concentration was attained at 5 minutes for artesunate and at 12 minutes for the 
metabolite dihydroartemisinin.The 4 hour area under the curve was calculated which is an 
equivalent of the drug exposure in each patient. 
The Cmax of artesunate was 6057.11 and that of dihydroartemisinin was 1256.66. 
Pk parameters of artesunate and DHA in adequate clinical and parasitological response 
Drug 4 Hour 
AUC(mean) 
4 hour 
AUC(median) 
SD Clearance(l/kg/hr) Cmax 
Artesunate 671.28 650.45 357.98 4.95 6057.11 
DHA 1158.58 884.80 800.34 3.41 1256.66 
 
Table 10 - PK parameters of artesunate and DHA in adequate clinical and 
parasitological response 
 
The dose distribution across time for artesunate and dihydroartemisin is summarised in 
Figure 18 and 19. 
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Figure 19 – Area under the concentration curve for artesunate in patients with 
adequate clinical and parasitological response. 
 
[X axis: 1 – 5 minutes,2 – 7 minutes,3 – 9 minutes,4 – 12 minutes,5 – 15 
minutes,6 – 20 minutes,7 – 30 minutes,8 – 45 minutes,9 – 60 minutes,10 – 90 
minutes,11 – 120 minutes,12 – 240 minutes] 
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Figure 20 – Area under the concentration curve for dihydroartemisinin for patients 
with adequate clinical and parasitological response 
 
[X axis: 1 – 5 minutes,2 – 7 minutes,3 – 9 minutes,4 – 12 minutes,5 – 15 
minutes,6 – 20 minutes,7 – 30 minutes,8 – 45 minutes,9 – 60 minutes,10 – 90 
minutes,11 – 120 minutes,12 – 240 minutes]   
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9.4.4 Pharmacokinetic parameters of artesunate and DHA among patients with 
delayed parasite clearance times (n=5) 
The pharmacokinetic of artesunate and dihydroartemisinin levels are tabulated for the 
patients with delayed parasite clearance times (Table 11).  
The peak concentration was attained at 5 minutes for artesunate and at 12 minutes for the 
metabolite dihydroartemisinin.  
The 4 hour area under the curve was calculated which was the equivalent of the drug 
exposure in each patient.  
The levels of dihydroartemisinin (4 hour exposure and maximum concentration) appear to be 
less in patients with delayed parasite clearance times when compared to the patients with 
adequate clinical and parasitological response. 
 
 Pk parameters of artesunate and dihydroartemisinin among patients with treatment failure 
Drug 4 hour 
AUC(Mean) 
4 hr 
AUC(Median) 
SD Clearance(l/kg/hr) Cmax 
Artesunate 569.77 587.17 195.60 5.22 5155.59 
DHA 733.63 798.48 262.06 4.13 989.98 
 
Table 11 - Pk parameters of artesunate and dihydroartemisinin among patients with treatment 
failure 
 
The dose distribution across time for artesunate and dihydroartemisinin is summarised in 
Figure 20 and 21 
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Figure 21 – Area under the concentration for artesunate in patients with treatment 
failure 
 
[X axis: 1 – trough levels,2 – 5 minutes,3 – 7 minutes,4 – 9 minutes,5 – 12 
minutes,6 – 15 minutes,7 – 20 minutes,8 – 30 minutes,9 – 45 minutes,10 – 60 
minutes,11 – 90 minutes,12 – 120 minutes,13 – 240 minutes]   
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Figure 22 – Area under the concentration curve for dihydroartemisinin in patients with 
treatment failure 
 
[X axis: 1 – 5 minutes,2– 7 minutes,3 – 9 minutes,4– 12 minutes,5 – 15 
minutes,6– 20 minutes,7 – 30 minutes,8– 45 minutes,9 – 60 minutes,10 – 90 
minutes,11 – 120 minutes,12 – 240 minutes]   
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9.4.5 INTER PERSON VARIABILITY OF DRUG CONCENTRATIONS 
 
There was significant inter person variability noted among the subjects, for the concentrations 
of artesunate and dihydroartemisinin. 
This was calculated using the formula :(Standard deviation/Mean)*100. 
This summarised in Table 12.  
INTER PERSON VARIABILITY OF PHARMACOKINETIC PARAMETERS 
VARIABLE ARTESUNATE 
VARIABILITY 
DIHYDROARTEMISININ 
VARIABILITY 
RESPONDERS 54.9% 67.7% 
TREATMENT FAILURES 36.7% 37.8% 
 
Table 12 – INTER PERSON VARIABILITY OF PHARMACOKINETIC 
PARAMETERS 
 
9.5 SUMMARY OF UNIVARIATE ANALYSIS – COMPARISON WITH ADEQUATE 
PARASITOLOGICAL RESPONSE AND DELAYED PARASITE CLEARANCE TIMES 
The baseline characteristics including the demographic variables, haematological, 
biochemical parameters were compared to identify factors which are associated with delayed 
parasite clearance times. This was done using the T test for equality of means and Levene‘s 
test for equality of variances. This is tabulated as follows :( APR – adequate parasitological 
response, DPR – delayed parasitological response) 
9.5.1 DEMOGRAPHIC VARIABLES 
 
Demographic variables which were compared between patients with adequate parasitological 
response and delayed clearance include occupation, history of travel to endemic areas and 
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geographic location. In view of the male preponderance, gender was not included in the 
univariate analysis.The distribution of patients with delayed clinical as well as parasitological 
clearance across different groups of occupation was similar. The difference was tested with 
Pearson‘s Chi square test and was not found to be statistically significant.The history of 
travel to malaria endemic areas as well as state of residence(Tamilnadu,Andhra Pradesh) 
were also correlated with Pearson‘s Chi square test and was found to be similar between the 
groups. 
9.5.2 CLINICAL VARIABLES 
 
The vital signs, especially the tachycardia and hypotension appear to be severe in the group 
with delayed parasitological clearance. However the difference in the clinical variables was 
correlated with t test, and was not found to be statistically significant between the two groups. 
The findings are summarised in Table 12. 
 CLINICAL VARIABLES ASSOCIATED WITH DELAYED PARASITOLOGICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN(APR) 
[+_sd] 
MEAN(DPR) 
[+_sd] 
95% CI (diff) p VALUE 
Age(years) 37.88(15.462) 36.69(9.268) -7.9 – 10.3 0.739 
Pulse rate(bts/min) 107.88(17.762) 112(23.580) 16.4 – 8.2 0.570 
Respiratory rate(Breaths/min) 24.98(7.898) 26.46(9.386) -8.9 – 3.1 0.613 
Systolic BP(mm Hg) 101.05(20.566) 92.31(31.132) -13.4 – 21.4 0.358 
Diastolic BP(mm Hg) 62.25(18.603) 58.46(18.187) 12.0 – 15.2 0.524 
Oxygen saturation 95.65(4.035) 94.77(5.134) -2.5 – 3.8 0.580 
Temperature(F) 101.4(2.107) 101.6(1.49) -2.3 – 0.5 0.647 
APR – Adequate parasitological response, DPR – Delayed parasitological response,DIFF – Difference, CI – Confidence interval 
Table 13 – Univariate analysis - CLINICAL VARIABLES ASSOCIATED WITH 
DELAYED PARASITOLOGICAL RESPONSE 
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9.5.3 HAEMATOLOGICAL PARAMETERS 
 
The severity of anaemia and thrombocytopenia was greater in patients with delayed parasite 
clearance times; however the mean difference was not statistically significant. 
The type of infection – falciparum and mixed infection (falciparum and vivax) were 
correlated with delayed clearance, using the Fisher‘s exact test and did not show any 
association with delayed clearance. This is summarised in Table 13. 
HAEMATOLOGICAL PARAMETERS ASSOCIATED WITH DELAYED PARASITOLOGICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN 
(APR)[+_sd] 
MEAN 
(DPR)[+_sd] 
MEAN DIFF 95% CI P VALUE 
Haemoglobin 
(gm/dl) 
11.02(2.91) 10.73(2.56) 0.29 -1.51 – 2.10 0.729 
Total leukocyte 
counts(cu mm) 
6314.63 
(4370.04) 
7423.08 
(2770.12) 
-1108.43 -3699.8 – 1482.9 0.289 
Platelets(cu mm) 61250 
(47835.58) 
40846 
(36066.71) 
20403.84 -8657.2 – 49464.9 0.115 
Prothrombin 
time(seconds) 
13.6(2.34) 14.43(2.18) -0.833 -4.37 – 2.70 0.611 
INR 1.23(0.19) 1.39(0.17) -0.162 -0.51 – 0.194 0.391 
Activated partial 
thromboplastin 
time(seconds) 
33.4(8.58) 35.1(4.38) -1.75 -13.7 – 10.2 0.670 
APR – Adequate parasitological response, DPR – Delayed parasitological response,DIFF – Difference, CI – 
Confidence interval 
Table 14 – Univariate analysis - HAEMATOLOGICAL PARAMETERS ASSOCIATED 
WITH DELAYED PARASITOLOGICAL RESPONSE 
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9.5.4 BIOCHEMICAL PARAMETERS 
 
On comparing the biochemical parameters, severe acute kidney injury and severe acute liver 
injury was noted in patients with delayed parasite clearance times as compared to the patients 
with adequate parasitological response. The bicarbonate levels were significantly lower in 
patients with delayed response, which was found to be statistically significant. This is 
summarised in Table 14 
 BIOCHEMICAL PARAMETERS ASSOCIATED WITH DELAYED PARASITOLOGICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN 
APR 
(+_sd) 
MEAN 
DPR 
(+_sd) 
MEAN 
DIFF. 
95% CI P VALUE 
Glucose(mg/dl) 115.42(32.9) 117.36(76.3) -1.9 -35.7 – 31.8 0.936 
Urea (mg%) 51.13(52.2) 106.15(85.6) -55 -95.1 - -14.9 0.045 
Creatinine(mg/dl) 1.46(1.1) 2.43(1.8) -0.96 -1.8 - -0.13 0.087 
Sodium(mmol/dl) 131.08(6.014) 132.15(5.6) -0.354 -4.16 – 3.45 0.849 
Potassium(mmol/dl) 4.01(0.62) 4.20(0.65) -0.195 -0.6 – 0.21 0.362 
Bicarbonate(mmol/dl) 20.08(4.81) 16.16(6.06) 3.919 0.52 – 7.31 0.058 
Total Bilirubin (mg %) 4.16(5.31) 8.75(6.96) -4.58 -8.26 - -0.9 0.016 
Direct Bilirubin (mg %) 2.16(4.53) 6.24(5.97) -3.68 -6.77 - -0.47 0.025 
Total Protein (mg %) 6.39(0.81) 5.93(0.98) 0.454 - 0.09 – 1 0.103 
Serum albumin (mg %) 3.21(0.63) 2.87(0.61) 0.335 -0.06 – 0.74 0.102 
Aspartate transferase(U/l) 47.43(36.3) 120.38(90.4) -72.96 -107.6 – 38.2 0.00 
Alanine transferase(U/l) 30.63(22.9) 53.92(32.87) -23.29 -41.77 - -5.41 0.012 
Alkaline phosphatase(U/l) 96.53(41.82) 87.38(29.2) 9.14 -15.66 – 33.94 0.463 
Lactate dehydrogenase(U/ml) 2000.07(1111.4) 1354.43(964.2) 645.64 -715.69 – 2006.94 0.324 
APR – Adequate parasitological response, DPR – Delayed parasitological response,DIFF – Difference, CI – Confidence interval 
Table 15 – Univariate analysis - BIOCHEMICAL PARAMETERS ASSOCIATED WITH 
DELAYED PARASITOLOGICAL RESPONSE 
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9.6 SUMMARY OF UNIVARIATE ANALYSIS – COMPARISON WITH ADEQUATE 
CLINICAL RESPONSE AND DELAYED FEVER CLEARANCE TIMES 
Delayed fever clearance time was defined fever defervescence more than 48 hours. The 
demographic variables, haematological, biochemical parameters were compared to identify 
factors which have a correlation with delayed fever clearance times. This was done using the 
T test for equality of means and Levene‘s test for equality of variances. This is tabulated as 
follows :( ACR – adequate clinical response, DPR – delayed clinical response). 
9.6.1 DEMOGRAPHIC VARIABLES 
 
Demographic variables like occupation, history of travel to endemic areas and geographic 
location were compared between patients with adequate clinical response and delayed 
clearance. 
 In view of the male preponderance, gender was not included in the univariate analysis. 
The distribution of patients with delayed clinical as well as parasitological clearance across 
different groups of occupation was similar. The difference was tested with Pearson‘s Chi 
square test and was not found to be statistically significant. 
The history of travel to malaria endemic areas as well as state of 
residence(Tamilnadu,Andhra Pradesh) were also correlated with Pearson‘s Chi square test 
and was found to be similar between the groups. 
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9.6.2 CLINICAL VARIABLES: 
 
The clinical variables are comparable between the two groups. The mean temperature at 
admission was 101 F in those with adequate clinical response and 102.2 F in those with 
prolonged fever defervescence.Both groups had tachycardia with low systolic blood 
pressures. There was no statistical difference between the two groups.This is summarised in 
Table 15. 
CLINICAL VARIABLES ASSOCIATED WITH DELAYED CLINICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN-ACR 
(+_sd) 
MEAN-DCR 
(+_sd) 
MEAN DIFF p VALUE 
Age(years) 37.29(14.8) 39.11(10.1) -1.8 0.728 
Pulse rate(bts/min) 109.7(20.2) 104.89(13.1) 4.8 0.498 
Respiratory 
rate(breaths/min) 
24.84(8.5) 27.78(6.2) -2.9 0.333 
Systolic BP(mm Hg) 99.59(25.1) 95.56(14.2) 4.0 0.644 
Diastolic BP(mm 
Hg) 
61.59(19.7) 60(10) 1.5 0.816 
Oxygen Saturation 95.55(4.6) 94.89(2.3) 0.65 0.680 
Temperature(F) 101.305(2.03) 102.22(1.43) -0.91 0.204 
ACR – Adequate clinical response, DCR – Delayed clinical response,DIFF – Difference, CI – Confidence 
interval 
Table 16 – Univariate analysis - CLINICAL VARIABLES ASSOCIATED WITH DELAYED 
CLINICAL RESPONSE 
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9.6.3 HAEMATOLOGICAL PARAMETERS 
 
On univariate analysis, the number of platelets appears to be different between the groups 
with 61795 in patients with adequate clinical response and 29111 in patients with prolonged 
fever defervescence.This difference was found to be statistically significant. The other 
parameters were comparable and no statistically significant difference was identified between 
the groups. This is summarised in Table 16. 
HAEMATOLOGICAL PARAMETERS ASSOCIATED WITH DELAYED CLINICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN-ACR 
(+_sd) 
MEAN-DCR 
(+_sd) 
MEAN 
DIFF. 
95% CI P 
VALUE 
Haemoglobin(gm/dl) 11.02(2.9) 10.6(1.9) 0.4 -1.6 – 2.4 0.701 
Total leukocyte counts 
(cu mm) 
6500(4269.9) 6988.8(2829.9) -488.889 -3479.6 – 2501.8 0.744 
Platelets(cu mm) 61795.45 
(47182.2) 
29111.11 
(25565.8) 
32684.3 7.447 – 65361.240 0.050 
Prothrombin time(seconds) 14.07(2.4) 12.75(0.35) 1.317 -2.71 – 5.34 0.479 
INR 1.27(0.2) 1.19(0) 0.08 -0.41 – 0.58 0.712 
Activated partial 
thromboplastin 
time(seconds) 
34.9(7.98) 29.1(1.48) 5.74 -7.467 – 19.05 0.349 
ACR – Adequate clinical response, DCR – Delayed clinical response,DIFF – Difference, CI – Confidence 
interval 
Table 17 – Univariate analysis - HAEMATOLOGICAL PARAMETERS ASSOCIATED 
WITH DELAYED CLINICAL RESPONSE 
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9.6.4 BIOCHEMICAL PARAMETERS: 
 
Among the biochemical parameters, the level of acute kidney injury, acute hepatic injury 
with hyperbilirubinemia and hypoalbuminemia appeared to be different between the two 
groups. The severity was higher in the group with delayed defervescence.The mean 
difference was found to be statistically significant. This is summarised in Table 17. 
BIOCHEMICAL PARAMETERS ASSOCIATED WITH DELAYED CLINICAL RESPONSE 
Summary of univariate analysis 
VARIABLE MEAN-ACR 
(+_sd) 
MEAN-DCR 
(+_sd) 
MEAN 
DIFF 
95% CI p VALUE 
Glucose(mg/dl) 112(31.9)  139.5(101.29) -27.5 -69.06 – 14.06 0.189 
Creatinine(mg/dl) 1.5(1.18) 2.9(1.83) -1.08 -2.04 - -0.12 0.027 
Urea (mg%) 56.84(58.1) 109.88(90.4) -53.08 -102.4 - -3.67 0.036 
Sodium(m mol/dl) 131.89(5.99) 131.89(5.62) -0.003 -4.36 – 4.36 0.999 
Potassium(m mol/dl) 4.03(0.604) 4.16(0.789) -0.124 -0.591 – 0.344 0.597 
Bicarbonate 19.5(5.44) 17.5(4.79) 1.94 -2.002 – 5.886 0.327 
Total Bilirubin (mg %) 4.57(5.75) 8.81(6.45) -4.23 -9.365 – 0.866 0.095 
Direct Bilirubin (mg %) 2.84(4.76) 6.76(5.78) -3.92 -8.493 – 0.641 0.085 
Total protein (mg %) 6.38(0.885) 5.76(0.602) 0.61 0.108 – 1.13 0.020 
Serum Albumin 3.20(0.665) 2.76(0.350) 0.43 0.118 – 0.757 0.009 
Alkaline 
phosphatase(U/l) 
91.89(39.47) 106(32.99) 0.279 -41.09 – 12.8 0.279 
Lactate 
dehydrogenase(U/l) 
1860.76(1212.42) 1778.62(957.17) 82.13 -1137.42 – 
1301.70 
0.886 
ACR – Adequate clinical response, DCR – Delayed clinical response,DIFF – Difference, CI – Confidence interval 
Table 18 – Univariate analysis - BIOCHEMICAL PARAMETERS ASSOCIATED WITH 
DELAYED CLINICAL RESPONSE 
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9.7 PARASITE INDEX AT ADMISSION 
 
The parasite index at admission was compared between two groups of adequate clinical and 
parasitological response (n = 35) and delayed parasite and fever clearance (n = 18)(Figure 
22).The difference was compared using the Mann Whitney U test. The difference was found 
to be statistically significant (p value – 0.027) 
 
Figure 23 – Parasite Index at admission 1 - Adequate Clinical and Parasitological 
Response, 2 – Delayed Clinical and Parasitological Response 
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9.8 UNIVARIATE ANALYSIS OF THE DRUG LEVELS (4 HOUR AUC) EXPOSURE – 
COMPARISON BETWEEN PATIENTS WITH DELAYED PARASITE CLEARANCE TIME 
AND ADEQUATE PARASITOLOGICAL RESPONSE 
(APR: Adequate parasitological response, DPR: Delayed parasitological response) 
 
The mean drug levels measured as the 4 hour area under the concentration curve obtained 
from the pharmacokinetic studies of artemisinin and metabolite dihydroartemisinin between 
patients with adequate parasite response(n = 4) and delayed parasite clearance(n = 4)was 
compared using the Mann – Whitney U test.  
The results are summarised in Table 18.  
DRUG CONCENTRATIONS AND TREATMENT FAILURE 
Summary of univariate analysis 
VARIABLE(number) MEAN 
(APR) 
STD 
DEVIATION 
(APR) 
MEAN 
(DPR) 
STD 
DEVIATION 
(DPR) 
P - 
VALUE 
ARTESUNATE 
(11) 
671.28 357.98 587.73 221.05 0.661 
DIHYDRO –
ARTEMISININ(4) 
1158.58 800.34 764.70 291.77 0.571 
APR – Adequate parasitological response, DPR – Delayed parasitological response,DIFF – 
Difference, CI – Confidence interval 
Table 19 – Univariate analysis - DRUG CONCENTRATIONS AND TREATMENT 
FAILURE 
 
The drug levels though appear to have lower levels in patients with delayed parasite 
clearance, this difference was not statistically significant. However the numbers in each arm 
would be a potential limitation to make any standard conclusion. 
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9.9 SUMMARY OF LOGISTIC REGRESSION ANALYSIS – COMPARISON BETWEEN 
PATIENTS WITH ADEQUATE PARASITOLOGICAL RESPONSE AND DELAYED 
PARASITE CLEARANCE TIMES 
 
The demographic variables, haematological parameters and biochemical parameters were 
categorically classified and a logistic regression analysis was done to identify those which 
might have an association or a trend towards causing a delay in parasite clearance times. 
The variables which were found to be statistically significant in univariate analysis were: age, 
creatinine, platelet counts, and parasite index at admission, total bilirubin and direct bilirubin 
levels. Age > 30 years was found to have an odds ratio of 5.717(95% CI – 0.845 – 38.9) 
which was not found to be statistically significant (p value – 0.075).This is summarised in 
Table 19. 
FACTORS ASSOCIATED WITH TREATMENT FAILURE(DELAYED PARASITOLOGICAL RESPONSE) 
Summary of multivariate logistic regression analysis 
VARIABLE VALUE ODDS RATIO 95% CI p VALUE 
Age(years) 30 5.717 (0.84 – 38.9) 0.075 
Platelet counts(cu mm) 50,000 2.217 (0.42 – 11.5) 0.343 
Creatinine(mg/dl) 1.2 1.436 (0.28 – 7.33) 0.664 
Parasite index at admission (%) 5 1.038 (0.95 – 1.12) 0.373 
Total Bilirubin (mg %) 2 1.480 (0.81 – 2.63) 0.200 
Direct Bilirubin (mg%) 0.5 0.740 (0.38 – 1.42) 0.368 
Table 20 – Multivariate logistic regression analysis - FACTORS ASSOCIATED WITH 
TREATMENT FAILURE (DELAYED PARASITOLOGICAL RESPONSE) 
 
The other parameters showed a positive odds ratio of association with delayed parasitological 
clearance; however it was not found to be statistically significant. 
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 The state/geographical area was categorised into two groups – TamilNadu and Andhra 
Pradesh. There was trend towards patients from Andhra Pradesh to have delayed parasite 
clearance times. The precise location is marked in the map (Figure 23, 24) 
 
Figure 24: Vellore map – Location of treatment resistant cases 
 Location of patients with delayed parasite clearance times 
 
Figure 25 – Chittoor map – Location of treatment resistant cases 
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9.10 SUMMARY OF LOGISTIC REGRESSION ANALYSIS – COMPARISON BETWEEN 
PATIENTS WITH ADEQUATE CLINICAL RESPONSE AND DELAYED FEVER 
CLEARANCE TIMES 
The demographic variables, haematological parameters and biochemical parameters were 
categorically classified and a logistic regression analysis was done to identify those which 
might have an association or a trend towards causing a delay in parasite clearance times. The 
variables which were found to be statistically significant in univariate analysis were: age, 
creatinine, platelet counts, and parasite index at admission, total bilirubin and direct bilirubin 
levels. Multivariate analysis showed a trend towards significance for thrombocytopenia and 
parasite index at admission to contribute to delay in parasite clearance times; however the 
difference was not statistically significant. This is summarised in Table 20. 
FACTORS ASSOCIATED WITH TREATMENT FAILURE(DELAYED CLINICAL RESPONSE) 
Summary of Multi variate logistic regression analysis 
VARIABLE VALUE ODDS RATIO 95% CI p VALUE 
Age(years) 30 2.240 (0.31 – 16.1) 0.423 
Platelet counts(cu mm) 50,000 3.416 (0.47 – 24.4) 0.222 
Creatinine (mg %) 1.2 2.710 (0.375 – 19.6) 2.710 
Parasite index at admission (%) 5 1.063 (0.98 – 1.14) 0.125 
Total Bilirubin (mg%) 1.5 0.766 (0.39 – 1.48) 0.428 
Direct Bilirubin (mg%) 0.5 1.449 (0.69 – 1.00) 0.318 
 
Table 21 – Multivariate logistic regression analysis – FACTORS ASSOCIATED WITH 
TREATMENT FAILURE 
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9.12 SUMMARY OF LOGISTIC REGRESSION ANALYSIS – COMPARISON OF HOST 
FACTORS WITH DRUG CONCENTRATIONS 
 
The mean exposure concentration of artesunate and dihydroartemisinin (active metabolite) 
measured by the area under concentration curve (0 – 240 mins) were compared with parasite 
clearance, parasite index at admission and the presence of acute kidney injury (elevated 
creatinine), to determine whether the drug concentrations of artesunate and the metabolite are 
different between: 
1) Responders and patients with delayed parasite clearance 
2) Patients with higher parasite index (PI>2%) 
3) Patients with renal failure (creatinine > 1.2 gm %) 
This was analysed using the multi variate logistic regression model if the drug concentrations 
vary in each of the above mentioned group.  
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9.12.1 ARTESUNATE MEAN AUC (0-240) CONCENTRATIONS 
 
The artesunate concentrations in patients with treatment failure were lower than those with 
adequate response. The mean difference showed a trend towards significance. 
The artesunate drug concentration was different between those with hyper parasitemia 
(PI>2%) and lower levels of parasitemia.This was found to be statistically significant.  
The drug levels were found to be higher in patients with renal failure, but the difference was 
not significant between the groups. The results for artesunate are summarised in table 21.  
FACTORS CONTRIBUTING TO DIFFERENCE IN ARTESUNATE LEVELS 
VARIABLE  MEAN DIFFERENCE(ng/ml) 95% CI p VALUE 
Delayed parasite 
clearance 
-285.42 -683.30 – 112.45 0.160 
Parasite Index at 
admission 
24.2 6.83 – 41.66 0.006 
Creatinine -5.083 -138.44 – 128.27 0.940 
Table 22 –Multi variate logistic regression - FACTORS CONTRIBUTING TO 
DIFFERENCE IN ARTESUNATE LEVELS 
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9.12.2 DIHYDROARTEMISININ (ACTIVE METABOLITE) MEAN AUC (0 – 240 mins) 
CONCENTRATIONS 
 
The dihydro artemisinin (active metabolite of artesunate) concentration in patients with 
treatment failure was also found to be lower than those with adequate response. The mean 
difference showed a trend towards significance. 
The dihydroartemisinin drug concentration was different between those with hyper 
parasitemia (PI>2%) and lower levels of parasitemia.This was found to be statistically 
significant.  
The drug levels were found to be higher in patients with renal failure, but the difference was 
not significant between the groups. The results for dihydroartemisinin are summarised in 
Table 22. 
FACTORS CAUSING DIFFERENCE IN DIHYDROARTEMISININ LEVELS 
VARIABLE MEAN 
DIFFERENCE(ng/ml) 
95% CI p VALUE 
Delayed parasite 
clearance 
-197.84 -450.76 – 55.07 0.125 
Parasite Index at 
admission 
14.63 2.712 – 26.563 0.016 
Creatinine 7.739 -63.801 – 79.28 0.832 
Table 23 - Multi variate logistic regression - FACTORS CONTRIBUTING TO 
DIFFERENCE IN DIHYDROARTEMISIN LEVELS 
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9.13 FACTORS ASSOCIATED WITH TREATMENT FAILURE - SUMMARY OF 
BOOTSTRAP ANALYSIS  
 
In view of the small sample size, a boot strap analysis was done to extrapolate those variables 
which were found significant or showed a trend towards significance to a larger population 
containing the same characteristics of the cohort. 
 The variables with p values <0.2 was taken into consideration. This included age, platelet 
counts, parasite index at admission, creatinine, total bilirubin and direct bilirubin. 
Age was found to be the only variable which was found to have difference in comparing 
patients with adequate parasitological response and treatment failure which was statistically 
significant [OR 1.7,p value – 0.012) 
The other variables were not found to have significant association with treatment failure. 
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10. DISCUSSION 
 
The advent of artemisinin based combination therapy has revolutionised the management of 
severe malaria, with significant mortality benefits when compared to quinine.(16, 17).The 
dynamic nature in which they rapidly clear the asexual forms of parasites and also block the 
pathogenesis of micro vascular sequestration, causing further host damage, make them the 
first line agents against this tropical disease. This further promoted the use of monotherapy, 
as well as marketing and distribution of ‗below the quality‘ drugs containing minimal 
amounts of artemisinin compounds leading to development of resistant strains(1,7,43,54). 
The present study describes a cohort of patients with malaria either caused only by 
falciparum species or as a mixed infection with vivax species presenting to a tertiary care 
referral hospital in Vellore, Tamil Nadu. 
The sample size was calculated assuming a 25% prevalence of treatment failure to 
artemisinin combination therapy, which was 75.However between the recruitment periods 
2012 – 2014, only 57 patients of slide confirmed falciparum malaria presented to our 
institution. This can be explained by the remarkably declining trend in the malaria cases in 
India as well in the state of Tamil Nadu,secondary to intensive preventive strategies including 
vector control measures(9,11). 
There might be a potential referral bias, as patient recruitment was institution based, which 
mainly caters to referred cases from different places in Tamil Nadu, and the neighbouring 
state Andhra Pradesh. The catchment areas are Vellore and surrounding areas and Chittoor in 
Andhra. 
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10.1 TREATMENT FAILURE WITH ARTEMISININ COMBINATION 
THERAPY 
 
The first correspondence by Noedl et al in 2008 of delayed parasite clearance times in 
western Cambodia(6),was described as ‗not so widespread epidemiological occurrence but 
might be a concern‘. However in less than a year‘s time, it promoted series of community 
based surveillance studies by Dondorp et al(5,54), identifying one of the biggest threats in 
management of malaria ‗ Artemisinin resistance‘. 
The proportion of patients with early treatment failure to artemisinin therapy in our cohort 
defined as presence of parasitemia(asexual ring stages on day 3 of ACT)(47),and as per the 
present updated definition, the proportion of patients fulfilling the criteria for partial 
artemisinin resistance(44) was 25.5%. 
The median parasite clearance time for the cohort was estimated to be 36 hours and median 
fever clearance time was 24 hours, which indicates the high overall efficacy of artemisinin 
for rapid clearance of the parasites by 48 hours. 
 Among the patients with delayed parasite clearance, the mean clearance time was found to 
be 77.53 hours. All the patients cleared parasites by 90 hours, and the maximum noted fever 
clearance time was 144 hours. 
Though the overall performance of artesunate in the form of rapidity of fever and parasite 
clearance is impressive, the proportion of patients with persistence of parasitemia is an 
alarming sign which requires further investigation to confirm the emergence of resistance in 
our population. 
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10.2 RECRUDESCENCE 
 
Recrudescence of malaria was traditionally defined as occurrence of fever within 8 weeks of 
initial infection(55).5 patients had relapse of fever post 7 days of treatment with artesunate, 
and the mean duration of the relapse defervescence was 54 hours.  
They did not fulfil the criteria for late clinical or parasitological failure(47),in view of 
absence of asexual ring forms in peripheral smears. However all of them had mature 
gametocyte stages, hence a low level parasitemia, not detectable by microscopy could be a 
possible explanation of recrudescence.  
Rescue therapy was given in all the patients with higher dose of artesunate (3.2 mg/kg) with 
change in the partner drug to intravenous clindamycin, which led to rapid fever 
defervescence. 
Ittarat et al (56)looked at a series of patients with recrudescence of falciparum infection and 
the association between host and parasite factors. They found that high parasite index at 
admission was found to have strong association with recrudescence rates. Presence of renal 
failure with uraemia at admission had a trend towards association.  
All of the 5 patients were with severe malaria at admission, with high parasite burden and 
multi organ dysfunction, hence with recrudescence. 
An extended follow up to 28 days or 42 days is required to further characterise the exact 
incidence of recrudescence and molecular PCR to detect low level parasitemia. 
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10.3 GAMETOCYTE CLEARANCE TIME AND TREATMENT FAILURE 
 
Another interesting finding in the results is the difference in the median gametocyte clearance 
times between responders and patients with treatment failure. However the limitation to this 
parameter was all patients were followed up till day 7 and those patients who required 
hospitalisation were followed till discharge. It was found to be 3.5 days among responders 
and 7 days among non responders. 
Studies have shown that gametocytemia in falciparum infections occur at 10 – 40 days after 
the parasitemia, and the longevity is documented to up to 21 days facilitating 
transmission(57).Piyaphanee et al studied the prevalence of gametocytemia post treatment 
with artemisinin combination therapy, and found 10%  on day 7 and 4% at day 14(58) as 
compared to ours which was 28% at day 7 and 6% > day 7. 
The prevalence of gametocytemia was found to be higher in our cohort when compared to the 
published studies assessing gametocyte clearance times. The prolonged gametocyte clearance 
might be the parasite factor enabling the spread of resistant strains.  
10.4 DEMOGRAPHIC CHARACTERISTICS AND TREATMENT FAILURE 
 
The patients in this cohort are young aged males (mean age: 37 years, range 17 – 75) and 
predominantly unskilled labourers mainly agriculture/field based workers. They are more 
predisposed to acquire malaria, in view of the close proximity to the vector breeding sites. 
The biting period of mosquitoes coincides with the peak activities of men predisposing them 
to acquire severe infection(59,60).However the distribution of patients with treatment failure 
was not different across the categories. 
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Age was found to have a statistically significant difference in patients who had adequate 
clinical and parasite clearance response compared with those patients with early treatment 
failure. Individuals with age more than 35 years have a strong trend towards treatment failure 
(OR 4.3, 95% CI 0.84 – 21). 
Sowunmi et al(8) looked at factors associated with delayed parasite clearance in  a cohort of 
African children, which showed age less than 2 was associated with delayed parasitological 
clearance. They attributed this to an impaired inbuilt immune response to enable efficient 
clearing of the parasites. The same hypothesis might be extrapolated in adults, as the 
production and migration of new B and T cells also show a decline with increasing age in 
adults, implying that the immune function declines with advancing age(61). 
The gender and occupation increase the chances of exposure to the vector but is not a 
contributing factor for delayed clearance. 
 A trend for treatment failure was identified towards patients residing in Andhra Pradesh 
(OR– 1.210, 95% CI (0.34 – 4.24).The detailed geographic mapping of their location is 
mentioned in the results section. The trend could be explained by the following ways: 
 1) Andhra Pradesh has increasing rates of vector borne diseases commonly malaria, 
chikungunya, dengue and scrub typhus which occurs in areas surrounded by forests, which 
are now subjected to urbanisation and improper deforestation practices with dissemination of 
vectors(62). 
2)The incidence of malaria is higher in Andhra when compared to Tamil Nadu.As of health 
status indicators in India – 2012,the state wise report of number of malaria cases, Andhra 
Pradesh reported 22723 as compared to Tamil Nadu, where the reported number was 
15486(10). 
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3) Inadequate drug dosages and use of monotherapy. 
4) Migrant population from the borders with acquired resistance to artemisinin. 
Though we do not have evidence to substantiate the last two reasons, this trend indicates the 
need for urgent surveillance studies of parasite clearance and fever clearance times to be 
conducted in Andhra Pradesh especially Chittoor. 
In Tamil Nadu, the patients with treatment failure are from Vellore, which has a common 
border with Chittoor, Andhra Pradesh, hence there is a likely chance of the spread of resistant 
parasites from the neighbouring state. This hypothesis requires further investigation, which 
would involve sequencing the genome of the parasite and clearance studies to be conducted 
in Andhra Pradesh. 
10.5 CLINICAL PRESENTATION AND TREATMENT FAILURE 
 
Malaria has a typical clinical presentation of  high fever with chills and rigors associated with 
excessive malaise, headache and fatigue(63).Published series showed the presence of fever in 
more than 92% of the subjects followed by headache and malaise as common 
symptoms(64).In travellers returning from endemic countries, the presence of fever with 
sweating ,absence of abdominal pain and overall poor general health were found to be 
important clinical predictors of malaria(65).In our cohort, all patients reported fever with 
headache, which was the most common presenting symptom. 
In a study of 1461 individuals by Dondorp et al(23), involving the South east Asian 
population, comparing the efficacy of artesunate over quinine in management of malaria, 
clinical jaundice was evident in 49% of the subjects. Clinical jaundice is the earliest sign of 
hepatic dysfunction, which can further progress to acute liver failure(66).In our study it was 
found to be 61.1%. 
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Pulmonary dysfunction is yet another complication of severe malaria. The incidence of the 
same published in case series by Sahu et al (67) comprising of hospitalised patients with 
falciparum malaria in intensive care was found to be 5.31%.In yet another series by Bruneel 
et al of 188 patients of severe falciparum malaria in intensive care(68) 14 patients had 
evidence of pulmonary  oedema and 2 patients had acute lung injury.22.78 % of the patients 
in our study had symptoms of respiratory distress at presentation. The cause of respiratory 
distress is multi factorial, which could be due to fever, presence of metabolic acidosis or lung 
injury.10 patients had acute pulmonary oedema and 5 patients had acute respiratory distress 
syndrome in our study. The mechanism of lung injury which was earlier postulated is that of 
pulmonary micro vascular sequestration of parasitized red blood cells, however a hypothesis 
of post treatment immune mediated destruction of alveolar membrane is yet to be proven(69). 
Cerebral malaria is defined as any alteration of mental status in a patient with malaria, in the 
absence of other potential causes to explain the same(64).The survivors usually do not have 
long term neurological sequelae.A significant proportion of 24.07% in our study had 
evidence of cerebral malaria at presentation. Though meningeal signs are reported to be 
rare(64),4 patients had terminal nuchal rigidity and 2 patients had generalised tonic clonic 
convulsions.1 patient had long term neurological sequelae in the form of persistent vegetative 
state. Brewster et al studied the predisposing  factors for the  development of long term 
sequelae in 604 Gambian children, and identified the severity of anaemia at presentation and 
seizures were found to be associated(70). 
22.4% of the patients in the study reported systemic bleed, in the form of haematuria, 
haematemesis and epistaxis.2 patients had disseminated intravascular coagulation. The 
bleeding manifestations are attributed to the degree of thrombocytopenia. The bleeding 
manifestations are secondary to the endothelial injury caused by the host – parasite 
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interaction. Systemic inflammation precipitates a state of disseminated intravascular 
coagulation(64). 
The clinical presentation was not found to vary among patients with adequate response and 
delayed clearance times. The severity of illness at presentation based on presence of fever, 
tachycardia, tachypnea, hypotension or hypoxia did not affect the parasite clearance or fever 
clearance. 
On a study conducted in African children with uncomplicated malaria who received oral 
artesunate (71),presence of fever and vomiting was associated with increased risk of delayed 
clearance, secondary to decreased bio availability of the drug. Currently there is scarcity of 
evidence correlating these parameters with artesunate. 
10.6 HAEMATOLOGICAL PARAMETERS AND TREATMENT FAILURE 
 
Patil et al (72)in their retrospective study of patients with falciparum malaria from Central 
India reported 46.8% of anaemia and only 2.12% of thrombocytopenia. Gupta et al looked at 
prevalence of thrombocytopenia in patients with vivax and falciparum infections, and found it 
to be 77.7% in falciparum infection.  
In our study we found 92.4 % of patients having thrombocytopenia and 51.8% have 
anemia.The proportion of patients who required product support was 27.7%,which was 
comparable to the published case series on severe malaria(67,68,73). 
In the univariate analysis, though the severity of anaemia and thrombocytopenia was found to 
higher in the group with delayed parasitological clearance, the difference was not found to be 
statistically significant. However this was limited by the low sample size, which was 
probably under powered to study this difference. 
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In patients with delayed fever defervescence, thrombocytopenia was found to be significantly 
severe with a mean difference of 32684.3/cu mm (95% CI: 7.447 - 65361.24, p value; 0.053). 
In the multivariate logistic regression analysis as well as in the boot strap analysis, presence 
thrombocytopenia or anaemia was not found to have an association with treatment failure. 
It has been shown in animal models(murine),clearance of parasites(Trypanasoma cruzi) 
require a complement mediated immune activation and adequate platelets to clear the 
infection(74).Thrombocytopenia was found to significantly delay the parasite clearance. 
In falciparum infection, the pathogenesis is a close interface between the immune and 
haematological system and platelets form the infrastructure on which the host directs the 
response. The relationship between delayed parasite clearance and these haematological 
alterations are yet to be deciphered. 
10.7 PARASITE INDEX AT ADMISSION AND TREATMENT FAILURE 
The mean parasite index of this cohort was 5.51 %( 0.1% – 48%: SD – 11.4) indicating 
hyperparsitemic. Hyperparasitemic is a indirect marker to indicate host immunity(75,76). In 
low endemic settings, the host immunity to malarial parasites (innate as well as acquired) is 
poor. Hence inoculation of parasites, with poor host immune response leads to excessive 
multiplication in the host, leading to hyperparasitemia. 
Stepniewska et al pooled the available data of parasite clearance times from multiple 
therapeutic efficacy studies conducted in different geographical territories to identify factors 
which determine the therapeutic responses(48). This was a large series involving 18,699 
patients and it revealed ,less than 5% of patients with low level parasitemia at admission 
(<100,000 parasites/µL) had detectable parasitemia on day 3, compared to 25% of patients 
with hyperparasitemia (>100,000 parasites/µL)(p <0.001). 
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In a study from Thailand(56),which was a retrospective study of 104 patients with falciparum 
malaria, of which 32 patients had proven recrudescence.Hyperparasitemia at admission, as 
defined as parasite density >10,000 micro/litre, was found to have 9 times higher likelihood 
of recrudescence. 
Univariate analysis comparing the parasite index at admission between the patients with 
adequate response and delayed clearance, showed higher parasite index in patients with 
delayed clearance (p value – 0.027). 
Multi variate logistic regression analysis also yielded a positive likelihood ratio of 1.063 
(95% CI: 0.98 – 1.14, p value – 0.125) .The difference was not found to be statistically 
significant, but there was trend towards association. 
Boot strap analysis failed to demonstrate any significant association with delayed clearance. 
This might be confounded with the lesser numbers of patients with low level parasitemia, 
leading to an unequal numbers in both arms for accurate comparison.  
Hyperparasitemia is an important factor for emergence of ‗de novo‘ resistance mutations. The 
presence of hyperparasitemia when compounded with inadequate antimalarial exposure 
accelerates emergence and spread of resistance strains(77). 
As hyperparasitemia is associated with delay in parasite clearance times, the currently 
adopted method is calculation of parasite clearance half life(78). This is calculated from the 
slope of the clearance curve got by plotting the log of parasitemia as measure by the parasite 
density against time. This will be an independent measure, not affected by the pre-treatment 
parasite density. The non availability of parasite density is a potential limitation in our study. 
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10.8 ACUTE KIDNEY INJURY AND TREATMENT FAILURE 
 
Acute kidney injury(AKI) is a common finding in severe falciparum malaria(73,79–81). The 
incidence of AKI varies from <1% to 40 % in falciparum malaria(81). 
The renal manifestations occur in two main forms: 
1) Chronic malarial nephropathy – predominantly seen in the African population, in view of 
continuous exposure to the pathogen 
2)Acute kidney injury, which predominates with falciparum infections in South East 
Asia(79). 
The pathogenesis of acute kidney injury in malaria is multifactorial. 
The commonly postulated mechanisms include obstruction of the microvasculature by 
parasitized red blood cells(sequestration),immune mediated glomerular and tubular 
damage,pre renal injury secondary to sepsis induced hypo perfusion and tissue 
hypoxia(64,79,81–84). In a large case series of AKI in malarial patients by Saravu et al,direct 
bilirubin was  found to be a risk factor for  renal dysfunction(82).  
In our study, acute kidney injury was seen in 53.70 %( n = 29), with 55% having prerenal 
azotemia which was comparable to other studies from India. Haemodialysis requirement was 
7% in our study, which was low when compared to the other published series(67,80,82,83). 
Univariate analysis revealed significant difference in the serum creatinine and urea levels 
between patients who responded adequately and in those with treatment failure. The mean 
difference was found to be statistically significant. Multivariate logistic regression models 
and boot strap analysis revealed a 2 times higher risk of treatment failure in the presence of 
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acute kidney injury; it was not of statistical significance. Currently there is a scarcity of 
evidence on association between presence of multi organ dysfunction and treatment failure. 
Acquired host immunity is currently identified to be the only factor deciding the clearance of 
parasites(85–87).This varies based on the endemicity of the region to malaria. Higher 
immunity accelerates clearance. 
10.9 ACUTE HEPATIC INJURY AND TREATMENT FAILURE 
 
The incidence of liver involvement in falciparum infections have been found to vary from 
2.58% to 68%(66,88–90).The most common direct attributable causes include that of malarial 
hepatitis which is classically described as a 3 or more fold elevation of liver enzymes in the 
presence of falciparum infection, with an excellent response to antimalarial therapy and 
secondly by intravascular haemolysis of  parasite laden red blood cells(88,91). 
In our study 75.9% of the patients had hepatic dysfunction, most commonly unconjugated 
hyperbilirubinemia with or without transaminitis, which is higher when compared to all the 
published case series in India(66,67,72,73,88–90). 
Univariate analysis revealed the presence of unconjugated hyperbilirubinemia and elevated 
SGPT >SGOT to be associated with treatment failure. The difference was found to be 
statistically significant. Hypoalbuminemia was strongly associated with delay in fever 
defervescence (p value – 0.006).This might be explained by the host immune response to the 
severity of infection, causing decrease in albumin, as it is a negative acute phase 
reactant.Multi variate regression analysis showed a trend towards association of direct 
bilirubin to treatment failure (OR -1.449; 95%CI 0.69 – 1; p – 0.318), however the difference 
was not statistically significant.  
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10.10 DRUG CONCENTRATIONS OF ARTESUNATE AND 
DIHYDROARTEMISININ AND TREATMENT FAILURE 
Intravenous artesunate is the recommended first line agent in management of severe 
falciparum malaria(2).Evidence from African as well as South east Asian population holds 
artesunate higher up when compared to quinine in terms of its excellent efficacy as well as 
the rapidity of parasite clearance(22,23). 
Our study subjects were administered intravenous artesunate at mean dose of 2.4 mg/kg and 
they achieved the plasma concentrations in a prompt manner. Very high plasma levels of 
artesunate and dihydroartemisinin were reached. The Cmax (maximum concentration) for 
artesunate was reached at 5 minutes and for dihydroartemisinin at 12 minutes, indicating a 
rapid conversion of artesunate to its active metabolite. This was also evident from other 
published literature in the world, which shows the Tmax( time to maximum concentration for 
artesunate to be less than 15 minutes and for dihydroartemisinin to be less than 25 
minutes(92–96). 
The drug cleared rapidly from the circulation, which was evident by the undetectable serum 
concentrations of artesunate as well its metabolite dihydroartemisinin by 120 minutes. In a 
review if pharmacokinetics of  artesunate compounds by Morris et al(93),the clearance for 
artesunate was found to be 2 – 3l/kg/hour and for dihydroartemisinin was 0.5 – 1.5l/kg/hour. 
In comparison to this our study population had higher rates of clearance of 4.95 and 3.41 
litre/kg/hour respectively. 
The maximum concentration (Cmax) of artesunate and dihydroartemisinin to a dose of 
2.4mg/kg was low in our cohort when compared to the published studies on patients with 
falciparum malaria. 
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The pharmacokinetic values comparing our cohort to different ethnicity are tabulated in table 
24. 
Table 24 - COMPARISON OF INTRAVENOUS ARTESUNATE AND DHA 
PHARMACOKINETICS IN DIFFERENT ETHNICITIES 
EVIDENCE(ETHNICITY) AS 
Cmax 
DHA  
Cmax 
AS 
AUC 
DHA 
AUC 
Clearance 
l/kg/hr[AS] 
Clearance 
l/kg/hr[DHA] 
PRESENT STUDY(INDIAN) 5867 573.33 650.45 884.80 5.085 3.72 
Byakika et al(97)(AFRICAN) 3260 3140 727 3492 180 32.25 
Batty et al(98)(VIETNAM) - 931 2980 8360 2.33 0.75 
Li et al(99)(KENYA) 28558 2932 1878 3543 1.7 0.73 
Newton et al(96)(THAILAND) 130 605 49 418 6.4 5.6 
 
4 studies were identified from different ethnicity, which assessed the pharmacokinetics of 
artesunate and dihydroartemisinin. 
One potential limitation in this comparison was that all these studies used intravenous 
artesunate as a bolus of 2.4 mg/kg, and the maximum concentration was obtained at the end 
of 2 minutes, when compared to our study where the maximum concentration was measured 
at the end of 5 minutes. In view of the rapid metabolism and half life of intravenous 
artesunate, the post 5 minute concentration, would be lower when compared to post 2 minute 
concentration. This would have falsely underestimated the maximum concentrations. 
An interesting trend to note is the rapidity in clearance of the drug in our population. Our 
clearance values are much higher when compared to other studies, which shows a significant 
variation in the pharmacogenomics when compared to other ethnicities.
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The question of whether our population requires higher dosing at baseline, needs to be 
answered through further research taking into account the proportion of treatment failure 
rates as well as the pharmacogenomics of the drug.  
To ensure adequate availability of pure drug in the compounds given to the patients we went 
ahead and estimated the concentration of pure drug in the usual compound given to our 
patients and we found that it was within the prescribed normal limits. 
Inter individual variation was noted between the concentrations of 4 hour AUC exposure and 
maximum concentrations (Cmax). In a study done on 17 patients with severe falciparum 
malaria in Thailand, more than 10 fold inter patient variability was found in the drug 
concentrations, leading to the recommendation of minimum dosage of 2.4 mg/kg in treatment 
of severe malaria(96).Previously published studies elaborating the pharmacokinetics of 
artesunate in severe  malaria, did not find any factors which altered drug concentrations or 
metabolism. (93,97,100). 
In our study, we compared the parasite index at admission with the mean AUC 
(0-240) 
of 
artesunate and dihydroartemisinin. Both the concentrations were found to be lower in patients 
with hyperparasitemia (PI>2%).This difference was found to be statistically significant. 
Hence in view of this significant difference of drug concentrations in patients with severe 
malaria, a higher dosing regimen is to be considered in patients with higher parasite burden. 
White et al ,on their review on factors causing selection of ‗de novo highly resistant mutant 
strains‘, have identified that low dosing regimens in hyperparasitemic individuals to 
contribute to the acquisition of resistance mutation and selection of the same to cause spread 
of resistance(77). 
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The metabolism of artesunate to dihydroartemisinin occurs in the liver, where the metabolites 
get glucuronidated and partly excreted in bile through faeces and partly cleared by 
urine(94,101).In our study, we compared the drug concentrations between subjects with acute 
kidney injury and normal renal function. The artesunate concentration was found to be lower 
in patients with AKI, but the concentrations of the metabolite dihydroartemisinin was higher 
in those subjects. This difference was not found to be statistically significant. This 
observation infers that there exists a difference in the concentration of the metabolite, hence 
the need for renal dose adjustment. There are potential dose related adverse effects described 
in literature which include delayed haemolysis and neurotoxicity(102–105). Hence the 
benefits of dose adjustment are to be interpreted based on long term follow up of the 
occurrence of side effects. 
Multiple landmark trials as well as small scale studies comparing the drug concentrations to 
parasite clearance have not established any difference in the drug levels between those with 
treatment failure and responders(96,97,106).In our study we found lower levels of artesunate 
and its metabolite dihydroartemisinin in patients with treatment failure, with a trend towards 
statistical significance. However the unequal distribution in both arms of comparison is a 
potential limiting factor in our population, for a definite conclusion. 
In the future, a larger study with equal numbers for comparison, with 2 minute duration of IV 
bolus, would be necessary for comparison between ethnicity and to clarify the 
pharmacogenomics and its clinical implications. 
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11. CONCLUSIONS 
 
Artemisinin resistance is an emerging threat in the Indian Subcontinent. The median fever 
clearance time was 24 hours and median parasite clearance time was 36 hours, indicating the 
high efficacy and rapidity of action of artemisinin in management of severe malaria.  
The incidence of treatment failure to ACT (artesunate+doxycyline/artemether+lumefantrine) 
in this cohort involving South Indian population with falciparum malaria was found to be 
25.5%. The proportion of recrudescence was 9.3%, requiring rescue therapy with higher dose 
of intravenous artesunate and change in the partner drug to clindamycin.The median 
gametocyte clearance time was higher in patients with treatment failure, indicating a higher 
risk of transmission of resistant parasites to the community. 
The drug concentrations of artesunate and metabolite dihydroartemisinin (DHA) for a mean 
dose of 2.4 mg/kg were lower in our cohort when compared to other cohorts from Vietnam, 
Cambodia and Thailand. The maximum serum concentrations are achieved in 5 minutes of 
dosing and is metabolised to DHA within 12 minutes of intravenous administration. The drug 
undergoes rapid clearance as evident by no detectable levels by 2 hours of dosing. Lower 
serum concentrations of the drugs were seen in hyperparsitemic individuals.  
A trend was identified towards Andhra Pradesh for origin of treatment resistance, especially 
in the state borders with Tamil Nadu. Higher age, presence of acute kidney injury, 
hyperbilirubinemia, metabolic acidosis and hyperparasitemia were found to be associated 
with treatment failure in the univariate analysis. Multivariate analysis revealed only age to be 
a risk factor for treatment failure. The drug levels were similar between responders and 
treatment failure. 
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12. LIMITATIONS 
 
1) The sample size was small, in view of the patient recruitment in the tertiary care referral 
centre. A community based study would have yielded more numbers. Other potential reason 
could be the fall in the number of malaria cases due to intense preventive and vector control 
measures in the state. 
2) Calculation of parasite density and parasite clearance half lives is a better indicator of 
treatment failure than the day 3 parasitemia rates. The estimation of parasite density for our 
patients requires further validation. 
3) The unequal number for comparison in the pharmacokinetic studies is a limitation to make 
any standard conclusion. 
4)More frequent sampling would have accurately estimated the clearance times, as a twelfth 
hourly estimate has a higher chance to over estimate clearance times, when compared to sixth 
or eighth hourly assessments. 
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ANNEXURE 1 
PATIENT INFORMATION SHEET 
TITLE: ASSESSMENT OF TREATMENT FAILURE WITH ARTEMISININ 
COMBINATION THERAPY IN PLASMODIUM FALCIPARUM MALARIA 
1) ABOUT THE STUDY: 
This study is done to assess whether the drug called artemisinin,which is a antimalarial drug 
is effective in clearing the malarial infection from the body as rapidly as it used to clear when 
it was introduced,that is within 48 hours.This study will also look at the number of patients 
who have delayed clearance of parasites from the blood following administration of this drug. 
2) PARTS OF THE STUDY: 
When you are identified to be an eligible candidate to be a part of the study, you will be 
approached by the doctor conducting the study. You will be asked a few questions about the 
details of your present illness and about your other underlying problems. You will be 
subjected to a thorough physical examination by the doctor. Following which you will be 
initiated on the medicines.Blood samples to check for parasites will be done twice daily till 
you clear the infection. On day 3 and day 7 you will be advised to follow up with a parasite 
count and index. 
3) RISKS INVOLVED IN PARTICIPATION: 
There are no risks involved in your participation in this study. You will receive the same 
treatment as given to a similar patient who is diagnosed with malaria and not a part of the 
study. 
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4)BENEFITS INVOLVED IN PARTICIPATION: 
Decreasing effectiveness  of this antimalarial medicine artesunate is a potential threat to 
emergence of resistance.The information we collect in this study will help us to identify the 
percentage of patients having early failure to therapy,hence can help in making guidelines to 
halt the process causing resistance and as well as to contain it. 
5)RESULTS OF THE STUDY: 
The results of the study will be compiled and will be put forth to the general information of 
public and professionals in the form of publications,posters or as presentations in 
conference.The information regarding you will only be handled by the doctor who conducts 
the study and others connected with the study. 
If you have more queries you can contact: 
Dr.T.Angel Miraclin 
PG registrar, General Medicine 
CMC,Vellore 
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ANNEXURE 1(b) 
PATIENT INFORMATION SHEET FOR PARTICIPANTS OF THE STUDY OF 
PHARMACOKINETICS OF ARTEMISININ(AS/DHA)  
PROJECT TITLE : ASSESSMENT OF TREATMENT FAILURE TO ARTEMISININ 
COMBINATION THERAPY IN PLASMODIUM FALCIPARUM MALARIA 
1)What is this study about? 
Following the diagnosis of severe malaria and hospitalisation,you will be initiated on 
Intravenous artesunate with oral doxycycline.There is a study which will be done to assess 
the declining effectiveness of this drug to clear parasites within 48 hours. On day 3 you will 
be enrolled in the second part of the study which will monitor the levels of this drug in your 
body.In exception to the routine we would like to assess the levels of artesunate and 
dihydroartemisinin in your blood three days after you are started on the 
medicine.Measurement of the drug levels,will reveal the actual difference in the levels 
between you and the other patients.Also your levels taken at different time periods will help 
to understand the variability of levels of artesunate and dihydroartemisinin in your blood at 
different selected time points. 
 2)How is it done? 
Following hospitalisation you will have a thorough physical examination and blood tests will 
be sent as a part of the standard of care by your treating physician.You will be started on IV 
artesunate which you will receive 3 doses at 2.4mg/kg each at 0,12 and 24 hours on day 
1,following that you will receive a once daily dosage. On day 3 you will be shifted to the 
clinical pharmacology laboratory by the doctor conducting this study. We will take a sample 
of blood(2 ml) for testing the levels of artesunate and dihydroartemisinin before giving the 
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day 3 dose.Following which an insyte will be inserted in the opposite arm to that of the insyte 
which delivers the drug.Artesunate will be given at dose of 2.4 mg/kg of your body 
weight.Then 2 ml of blood will be collected from you at regular intervals to get a total of 10 
samples.Using the 10 samples ,we will have an understanding of the amount of artesunate 
and dihydroartemisinin present in your blood in between the two dosing periods. 
3)Expenses involved? 
You will not be required to pay for any of the level tests for artesunate or dihydroartemisinin 
at any point of time. 
4)Risks Involved? 
There are no potential risks involved in participating in this study. 
 
Participation  in this study is entirely voluntary and you  may say no to taking  part at any 
point of time.If  you decide you do not want to be included in the study this will not affect 
your further management in this hospital. 
In case of more queries: 
Dr.T.Angel Miraclin 
PG Registrar,General Medicine 
CMC,Vellore. 
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ANNEXURE 2 
Study Title: Assessment of treatment failure to artemisinin combination therapy in treatment of 
Severe malaria. 
Subject‘s Initials: _________ Subject‘s Name: ________ 
Date of Birth / Age:_______ 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor‘s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory‘s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator‘s Name: _________________________ 
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ANNEXURE 3 
PROFORMA – ASSESSMENT OF TREATMENT FAILURE TO ARTEMISININ 
COMBINATION THERAPY PRESENTING TO A TERTIARY CARE HOSPITAL: 
---------------------------------------------------------------------------------------------------------------------------
----------Name:                                                               Age:         Sex:M/F         Date of visit:                 
Occupation:  HW/STU/BUS/AGRI/LAB/OFFICE/.........................           H.NO: 
State:TN/AP/OTHERS Ph NO:                                                IP/OP     Ward: I/C/E/MTS4 
/MHDU/MICU/ED     
RECENT TRAVEL:Y/N                                                                MONO/MIXED 
HTN Yes/No CKD Yes/No   CVA    Yes/No          CLD       Yes/No 
DM Yes/No IHD Yes/No    HIV    Yes/No        COPD        Yes/No 
 
SYMPTOM DURATIO
N 
 D-0 D-3          D- 7 
FEVER   Yes/No Yes/No        Yes/No 
ALTEREDSENSORIUM   Yes/No Yes/No        Yes/No 
RESPI DISTRESS   Yes/No Yes/No        Yes/No 
CONVULSIONS Yes/No GTCS/FOCAL Yes/No Yes/No        Yes/No 
BLEEDING Yes/No EPI/ORAL/UGI/LGI/
UT 
Yes/No Yes/No        Yes/No 
HEADACHE   Yes/No Yes/No        Yes/No 
JAUNDICE   Yes/No Yes/No        Yes/No 
 
PR           /min SPO
2 
          
% 
ICTERUS Yes/No LIVER Yes/No 
BP           /          mm 
HG 
TEM  CREPITATIO
NS 
Yes/No SPLEEN Yes/No 
RR           /min GCS        /15 DROWSINESS Yes/No NECKSTIF
F 
Yes/No 
 
Hb  Glucose  TB/DB                  / 
TC             Creat/Urea        / Prot/Alb                 / 
Neutrophil  Na/K/HCO3       /        / OT/PT                / 
Lymphocytes  pH  A.PHOS  
Left shift Yes/No BF -       
% 
Bacteremia Yes/No CPK  
Platelets  Organism  CKMB/TRP  
Procal  CSF TC  N/L/GLU/PROT        /        /         / 
 
CXR Normal/Consolidation/Pleural effusion/Alveolar infiltrates/post infectious sequelae 
USG Hepatomegaly/Splenomegaly/Free fluid/GB wall thickening/ 
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CT 
BRAIN 
Meningeal  enhancement/Infarct/bleed 
 
Supports Oxygen     NIV    IV     
Dialysis 
         Inotropes  1/2/3 
Duration     Dopa  Norad    Adr      vaso 
TRANSFUSION PC= PRC= FFP= CRYO=   
 
UGI SCOPY 
 
Yes/No 
 
Colonoscopy 
 
Yes/No 
 
Findings: 
Nosocomial infec tion– Yes/No 
 
VAP/UTI/CRBSI/Thrombophlebitis 
 
        DYSFUN LEVEL 0 LEVEL I     LEVEL II     LEVEL III 
GCS 14 – 15(0) 10 – 13(1)       7 – 9(3)      0 – 6(5) 
Urea 
Creatinine 
UrineOutput 
10-36(0) 
0.6 – 1.2(0) 
0.75 -3.9(0) 
37-59(1) 
1.3 – 1.9(1) 
0.5-0.75(1) 
 
     60-119(3) 
     2 -4.9(3) 
     0.4 – 
0.5(3) 
     >120(5) 
     >5(5) 
     <0.5(5) 
HR 
SYST BP 
51 – 119(0) 
90 – 160(0) 
120-139(1) 
70 – 89(1) 
   >140 OR 
<51(3) 
   41 – 59(3) 
 
RR 20 -30(0) 31 – 40(1)    >41(3)  
Hb(gm/dl) 
TLC(/cu mm) 
Platelet 
10 -13.9(0) 
4001-16000(0) 
80K – 2,50K(0) 
7 -9.9(1) 
2001-
4000,>10000(1) 
<80000(1) 
   <7(3) 
   <2000(3) 
 
 
S.BILIRUBIN <2(0) >2(1)   
GLUCOSE(mg/dl) 60 -110(0) <60(1)   
SCORE RISK  
  <5 LOW 
6 – 11 INTERMEDIATE 
>12 HIGH 
REGIMEN: [Artesunate+doxycycline] [Artemether+lumefantrine]    [Artesunate+clindamycin]                                                                                                 
EMPIRICAL ANTIBIOTIC: YES/NO          If yes,what antibiotic: 
If treatment failure- regimen 
FEVER DOCUMENTATION 
 
DAY 
12AM -6AM 6AM – 
12PM 
12PM -
6PM 
6PM -12AM       <24hr          Yes/no 
1 Yes/No Yes/No Yes/No Yes/No        24-48h          Yes/no 
2 Yes/No Yes/No Yes/No Yes/No        48-72h          Yes/no 
3 Yes/No Yes/No Yes/No Yes/No        >72h          Yes/no 
7 Yes/No Yes/No Yes/No Yes/No 
PARASITES DOCUMENTATION 
DA
Y 
RINGSMORNIN
G 
PI EVENIN
G 
PI GAMETOCYT
ES 
<24hr Yes/no 
1 Yes/No  Yes/No         Yes/No 24-
48h 
Yes/no 
2 Yes/No  Yes/No         Yes/No 48-
72h 
Yes/no 
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3 Yes/No  Yes/No         Yes/No >72h Yes/no 
7 Yes/No       X         Yes/No 
DURATION OF ADMISSION:                                             
OUTCOMES:ETF/LTF/ACPR/DEATH 
IN CASE OF LTF 
DAY SEVERE 
MALARIA 
Fever Parasites(rings) Gametocytes 
14 Yes/no Yes/no Yes/no Yes/no 
21 Yes/no Yes/no Yes/no Yes/no 
28 Yes/no Yes/no Yes/no Yes/no 
 
INCLUDED FOR PHARMACOKINETIC STUDIES: YES/NO 
 BLOOD SAMPLES STORED FOR GENETIC ANALYSIS:  YES/NO 
 
 
 
